cyclosporine has been researched along with Dry Eye Syndromes in 246 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 58 (23.58) | 29.6817 |
| 2010's | 127 (51.63) | 24.3611 |
| 2020's | 61 (24.80) | 2.80 |
| Authors | Studies |
|---|---|
| Gupta, PK; Karpecki, P; Mitchell, B; Toyos, M | 1 |
| Boehmer, BE; Ciolino, JB; Krösser, S; McLaurin, E; Meides, AS; Ousler, GW; Schlüter, T; Sheppard, JD; Usner, D; Wirta, DL | 1 |
| Ariño-Gutiérrez, M; Arriola-Villalobos, P; Benitez-Del-Castillo, JM; Burgos-Blasco, B; Diaz-Valle, D; Oribio-Quinto, C; Vidal-Villegas, B | 1 |
| Al-Kinani, AA; Alany, RG; Burgalassi, S; Chetoni, P; Chipala, E; Monti, D; Tampucci, S; Terreni, E; Zucchetti, E | 1 |
| Annavajjhala, S; D'Souza, S; Mohapatra, A; Mullick, R; Shetty, R; Thakur, P | 1 |
| Choi, SH; Day, AJ; Dodd, RJ; Kim, HJ; Kim, YJ; Kouvatsos, N; Milner, CM; Oh, JY; Ryu, JS | 1 |
| Anand, A; Huang, CC; Huang, YF; Jian, HJ; Lai, JY; Li, YJ; Lin, HJ; Lin, PH | 1 |
| Choi, Y; Eom, Y; Kim, HM; Park, SY; Rhim, JW; Song, JS; Yoon, EG | 1 |
| Sang Min, J; Shin, D | 1 |
| Aschenbrenner, DS | 1 |
| Gibson, AA; Hendrix, LH; Macsai, M; Sun, L; Tam, I; Visco, DM | 1 |
| Baudouin, C; Labetoulle, M; Leonardi, A; Pisella, PJ | 1 |
| Gao, M; Kong, X; Liang, R; Zhao, L; Zhao, Q; Zhu, Q | 1 |
| Jiang, X; Jie, Y; Jin, X; Li, X; Peng, W; Wu, M; You, Z; Zhou, Q; Zhou, S; Zhu, L | 1 |
| Birangal, S; Chaudhari, P; Ghate, V; Kodoth, AK; Lewis, SA; Mallela, LS; Mavlankar, N; Nampoothiri, M; Pal, A; Roy, S | 1 |
| Abraham, AG; Gregory, D; Hauswirth, S; Ifantides, C; Li, T; Liu, SH; Rittiphairoj, T; Saldanha, IJ | 1 |
| Choi, CY; Chung, JK; Chung, SH; Chung, TY; Hwang, HS; Hwang, KY; Hyon, JY; Kim, DH; Kim, JH; Kim, JY; Kim, KW; Kim, S; Lee, HK; Lee, JE | 1 |
| Ahmad, S; Baudouin, C; Benitez Del Castillo, JM; Messmer, EM; Mrukwa-Kominek, E; Rolando, M; Vitovska, O | 1 |
| Amrane, M; Aragona, P; Bremond-Gignac, D; Doan, S; Ismail, D; Leonardi, A; Montero, J; Németh, J | 1 |
| Altan-Yaycıoğlu, R; Aydın Akova, Y; Dönmez, O | 1 |
| Jee, JP; Jin, R; Kim, HJ; Kim, J; Mondal, H; Yoon, HJ; Yoon, KC | 1 |
| Goswami, A; Kaur, M; Maharana, PK; Pandey, RM; Sharma, N; Titiyal, JS; Velpandian, T | 1 |
| Bi, Z; Chen, C; Li, Y; Liang, Y; Liu, S; Shen, J; Yin, X; Zhao, X | 1 |
| Acuna, KA; Betz, J; Galor, A; Locatelli, EVT; Tovar, AA | 1 |
| Basu, S; Batra, N; Chauhan, T; Gupta, A; Gupta, V; Mukherjee, S; Rao, AT; Sangwan, VS; Sharma, N | 1 |
| Akpek, EK; Ciolino, JB; Downing, JE; Krösser, S; Meides, AS; Sheppard, JD; Tauber, J; Wirta, DL | 1 |
| Bai, S; Cao, Z; Chen, Y; Gui, S; He, N; Liu, Y; Shan, S; Wu, J; Zheng, Z | 1 |
| Brzheskiy, VV | 1 |
| An, WJ; Choi, CY; Chung, TY; Jeon, S; Jeong, SJ; Jung, GT; Kim, HS; Kim, KP; Kim, M; Kim, TI; Lee, HK; Lee, HS; Song, JS | 1 |
| Gibson, AA; Hauswirth, SG; Hemphill, M; Hendrix, LH; Kabat, AG; Somaiya, K | 1 |
| Liu, J; Liu, Y; Wong, KY; Wong, MS; Zhou, L | 1 |
| Baek, J; Kim, EC; Kim, HS; Kim, MS; Lee, JY; So, HR | 1 |
| Abe, K; Ait-Oufella, H; Alacamli, G; Alacamli, OG; Amir, O; Antar, S; Ashour, H; Azimonti, G; Baba, Y; Balogun, MM; Bampidis, V; Bastos, ML; Ben Hamouda, N; Bickel Haase, T; Bjornsson, R; Bostan, M; Braik, R; Brantom, P; Briggs, S; Bujor, I; Canbek, TD; Cherecheanu, AP; Chesson, A; Choudhary, RJ; Christensen, H; Chung, HR; Clavier, T; Dahman, NBH; Dani, S; Demailly, Z; Devine, LD; Ding, G; Duan, X; Durjava, M; Dusemund, B; Edebali, S; Elbaz Greener, G; Elnoby, AS; Fang, Q; Fares, AM; Fashola, MB; Fawzy, MS; Fouad, FM; Fu, SZ; Fujita, S; Furusawa, S; Gallagher, AM; Gao, J; Goyal, N; Guo, J; Hamuda, N; Han, Y; Hariri, G; Heist, EK; Hill, AJ; Homoud, M; Hu, Q; Hu, Z; Huang, L; Ide, T; Ikeda, M; Ishimaru, K; Jiang, C; Kaderli, ST; Kanamura, T; Karalezli, A; Kaur, P; Kazatsker, M; Kobo, O; Kouba, M; Kumar, R; Lavillegrand, JR; Leshem, E; Li, A; Li, S; Liu, R; López Puente, S; López-Alonso, M; Ma, M; Madias, C; Manini, P; Marcon, F; Margolis, G; Matsushima, S; Mayo, B; Miller, JE; Miyake, R; Miyamoto, HD; Naumann-Gola, S; Ortner, E; Pandit, R; Pang, Y; Pechová, A; Petkova, M; Pîrvulescu, R; Popa-Cherecheanu, A; Ramos, F; Roguin, A; Rozen, G; Ruskin, JN; Sanz, Y; Schweiggert-Weisz, U; Shafie, AAA; Sharma, H; Shi, X; Stoicescu, EA; Stopyra, W; Suh, JD; Sul, S; Tamion, F; Tiu, C; Tohyama, T; Tsutsui, H; Tsutsui, Y; Vandestienne, M; Villa, RE; Wang, P; Watanabe, M; Westendorf, J; Woutersen, R; Xia, J; Xing, W; Xu, X; Yang, L; Yang, N; Yu, J; Yu, M; Yu, X; Zhang, L; Zhao, Y; Zhao, Z; Zhou, X; Zorn, H | 1 |
| Bhargava, R; Pandey, K; Rajpoot, M; Singh, D | 1 |
| Jia, F; Jiang, L; Jin, H; Li, Z; Xu, W; Zhao, X | 1 |
| Chang, I; Choi, JS; Jin, R; Kim, J; Kim, Y; Li, L; Li, Y; Pan, SH; Yoon, HJ; Yoon, HS; Yoon, KC | 1 |
| Barghout, V; Huynh, L; Karpecki, P; Khanal, A; Matossian, C; Mitchell, B; Schenkel, B; Yenikomshian, M; Zanardo, E | 1 |
| Lee, D; Lee, GW; Yoon, SH | 1 |
| Akpek, EK; de Paiva, CS; Ng, SM; Pflugfelder, SC | 1 |
| Hyun, S; Li, L; Yoon, KC; Yu, J | 1 |
| Chachaj-Brekiesz, A; Dynarowicz-Latka, P; Kobierski, J; Lipiec, E; Wnętrzak, A | 1 |
| Adhikari, N; Bang, SP; Jun, JH; Kim, H; Kim, JY; Lee, DC; Lee, HG; Neupane, S; Son, MJ; Yeon, CY | 1 |
| Choi, CY; Ji, YW; Kim, HM; Kim, HS; Kim, KP; Kim, MJ; Lee, HK; Oh, JW; Ryu, SY; Seo, KY; Song, JS; Yeo, A | 1 |
| Hmingthansanga, V; Katari, O; Pawde, DM; Rahman, SNR; Shunmugaperumal, T | 1 |
| Hwang, SB; Kang, DH; Kang, SS; Kim, JY; Lee, JH; Lee, JY; Oh, SJ; Park, JH; Tchah, H | 1 |
| Huang, J; Liu, YX; Ren, GF; Wang, H; Wang, Q; Zhu, L; Zhuang, YL | 1 |
| Chi, SC; Kang, YN; Tuan, HI | 1 |
| Cox, SM; Nichols, KK; Osei, KA | 1 |
| Lin, MC; Neri, P; Perez, VL; Periman, LM; Saban, DR | 1 |
| Beckman, K; Katz, J; Majmudar, P; Rostov, A | 1 |
| Jacobi, C; Paulsen, F; Schneider, E | 1 |
| Sridhar, U; Tripathy, K | 1 |
| Kumar, PR; Sahai, A; Shamshad, MA; Trivedi, GK; Tyagi, L; Watts, P | 1 |
| Baudouin, C; Lim Bon Siong, R; Puangsricharern, V; Sun, CC; Tong, L; Yoon, KC | 1 |
| Gehlsen, U; Siebelmann, S; Steven, P | 1 |
| Deng, Y; Ge, Y; Gou, J; He, H; Ran, M; Shang, L; Sun, R; Tang, X; Tao, X; Wang, Y; Yin, T; Zhang, A; Zhang, Y; Zhu, Y | 1 |
| Botella García, J; de la Paz, MF; Lázaro-Rodríguez, V | 1 |
| Hu, JY; Liu, ZG; Yang, YR | 1 |
| Evans, DG; Karpecki, PM; Nichols, KK | 1 |
| Chen, Y; Hu, J; Huang, C; Li, W; Lin, X; Liu, Z; Ouyang, W; Tang, L; Wu, J; Wu, Y; Yang, Y; Zhang, X; Zheng, X; Zhou, Y | 1 |
| Cubuk, MO; Ozgur, A; Ozulken, K; Ucgul, AY; Yuksel, E | 1 |
| El Zawahry, O; Hassanein, D; Moawad, P; Ragab, G; Shamma, R | 1 |
| Chen, RX; Dai, H; Gao, ZQ; Li, XY; Li, Y; Peng, WY; Zhou, SY; Zhu, L | 1 |
| Barabino, S; Daull, P; Feraille, L; Garrigue, JS; Gros, E; Nagano, T | 1 |
| Deshmukh, R; Dua, HS; Elsahn, A; Mohammed, I; Said, DG; Ting, DSJ | 1 |
| Atilla, H; Bingöl Kızıltunç, P; Büyüktepe, TÇ; Ertem, M; İleri, T; İnce, E; Yalçındağ, FN | 1 |
| Amrane, M; Baudouin, C; Bonini, S; Figueiredo, FC; Garrigue, JS; Ismail, D; Leonardi, A; Messmer, EM | 1 |
| Chee, SP; Siak, J | 1 |
| Asbell, PA; Kuklinski, E | 1 |
| Crnej, A; Dana, R; Hamrah, P; Kheirkhah, A; Mullins, A; Ren, A; Satitpitakul, V; Schaumberg, D | 1 |
| Amrane, M; Baudouin, C; de la Maza, MS; Figueiredo, FC; Garrigue, JS; Ismail, D; Leonardi, A | 1 |
| Choi, CY; Hyon, JY; Kim, HS; Kim, JH; Kim, TI; Shin, KU; Yoon, KC | 1 |
| Ahn, BN; Kim, CE; Lee, H; Yang, J | 1 |
| Akpek, EK; Dickersin, K; Hutfless, ST; Saldanha, IJ | 1 |
| Clearkin, L | 1 |
| Amrane, M; Baudouin, C; Figueiredo, FC; Garrigue, JS; Ismail, D; Leonardi, A; Van Setten, G | 2 |
| Cheng, AMS; Sheha, H; Tighe, S; Tseng, SCG | 1 |
| Kumar, LR | 1 |
| Cagini, C; Cerquaglia, A; Cillino, S; Dua, HS; Fiore, T; Iaccheri, B; Lupidi, M; Torroni, G | 1 |
| Baudouin, C; Bouillot, A; Labbé, A; Rouimi, F | 1 |
| Boujnah, Y; Burillon, C; Dot, C; El-Chehab, H; Kocaba, V; Mouchel, R | 1 |
| Amrane, M; Baudouin, C; Figueiredo, FC; Garrigue, JS; Ismail, D; Labetoulle, M; Leonardi, A; Messmer, EM; Sainz-de-la-Maza, M | 1 |
| Chen, D; Li, Y; Shen, Y; Tu, J; Yang, W; Yu, Y | 1 |
| Boboridis, KG; Konstas, AGP | 1 |
| Kang, S; Kim, CE; Kim, K; Kleinman, HK; Ousler, GW; Sosne, G; Yang, J | 1 |
| Chen, ZM; Huang, WL; Lin, BW; Wang, L | 1 |
| Beak, JU; Chun, YH; Kim, HS; Na, KS | 1 |
| Bradley, JL; Dana, R; Evans, AM; Guerin, A; Pivneva, I; Stillman, IÖ | 1 |
| Ji, YW; Kang, HG; Kim, HC; Lee, HK; Moon, I; Noh, H; Song, JS; Yeo, A | 1 |
| Akpek, EK; Amescua, G; Dunn, SP; Farid, M; Garcia-Ferrer, FJ; Lin, A; Mah, FS; Musch, DC; Rhee, MK; Varu, DM | 1 |
| Amrane, M; Baudouin, C; de la Maza, MS; Garhöfer, G; Garrigue, JS; Ismail, D; Labetoulle, M; Leonardi, A | 1 |
| Hind, J; Lockington, D; Macdonald, E | 1 |
| Choi, JH; Choi, JS; Choi, W; Jin, R; Ju, HT; Lee, WJ; Li, Y; Moon, MJ; Shrestha, T; Yoon, KC | 1 |
| Gote, V; Mandal, A; Mitra, AK; Ogundele, A; Pal, D | 1 |
| Barabino, S; Baudouin, C; Daull, P; Docquier, M; Feraille, L; Garrigue, JS; Kessal, K; Parsadaniantz, SM | 1 |
| Beckert, M; Ciolino, JB; Jentsch, G; Krösser, S; Lonsdale, JD; Moreira, HR; Ousler, GW; Steven, P; Torkildsen, GL; Wirta, DL | 1 |
| Goldberg, DF; Justice, A; Malhotra, RP; Schechter, BA; Sheppard, JD; Weiss, SL | 1 |
| Cheon, EJ; Chou, M; Chung, SH; Hwang, J; Kang, MJ; Kim, YH; Lee, HJ | 1 |
| Gan, L; Liu, Y; Wang, Y; Yang, J; Zhang, H | 1 |
| Choi, CY; Chung, TY; Kim, EC; Kim, HK; Kim, HS; Kim, JY; Kim, MK; Kim, TI; Lee, DH; Lee, HK; Park, CH; Song, JS; Yoon, KC | 2 |
| Choi, YH; Kim, DH; Kim, MK; Kim, Y; Paik, HJ | 1 |
| Braghiroli, M; Demarinis, G; Fossarello, M; Iovino, C; Napoli, PE | 1 |
| Bian, A; Chen, D; Chen, W; Deng, Y; Hong, J; Shao, Y; Zhang, M; Zhang, S; Zhao, J | 1 |
| Akpek, EK; Smith, RA | 1 |
| Cardarelli, WJ; Smith, RA | 1 |
| Chung, SK; Chung, YW; Oh, TH | 1 |
| Amparo, F; Dana, R; Hamrah, P; Jin, Y; Schaumberg, DA | 1 |
| Bonini, S; Lambiase, A; Mantelli, F; Mastropasqua, A; Merlo, D; Sacchetti, M | 1 |
| Devecı, H; Kobak, S | 1 |
| Aragona, P | 1 |
| Choi, C; Chung, E; Hyon, JY; Kim, HM; Lee, D; Lee, J; Song, JS | 1 |
| Wei, RL; Zhou, XQ | 1 |
| Han, JW; Jang, SY; Yoon, JS | 1 |
| Donnenfeld, ED; Holland, EJ; Lane, SS; McDonald, MB; Perry, HD; Pflugfelder, SC; Samudre, SS; Sheppard, JD; Slonim, CB; Solomon, KD; Solomon, R | 1 |
| Bielory, L; Kumar, S; Syed, BA | 1 |
| Hwang, SJ; Jin, SE; Kang, H; Karn, PR; Kim, HD; Sun, BK | 1 |
| Santhiago, MR; Torricelli, AA; Wilson, SE | 1 |
| Lee, NY; Lyu, B; Oh, SH; Yim, HB | 1 |
| Boynton, GE; Hussain, M; Mian, SI; Niziol, LM; Raoof, D | 1 |
| Chen, LJ; Wan, KH; Young, AL | 1 |
| Kim, C; Kleinman, HK; Sosne, G | 1 |
| Choi, W; Kim, N; Yang, JM; Yoon, KC | 1 |
| Acir, NO; Cetinkaya, S; Cetinkaya, YF; Dadaci, Z; Mestan, E; Yener, HI | 1 |
| Downie, LE; Keller, PR | 1 |
| Xiao, W; Xu, GT; Ye, W; Zhang, J; Zhang, Y | 1 |
| Igras, E; Kennedy, S; MacDermott, EJ; Murphy, CC | 1 |
| Ciurtin, C; Cojocaru, VM; Isenberg, DA; Ostas, A; Walsh, SB | 1 |
| Chow, J; Elia, M; Materin, MA; Nguyen, AT; Sznol, M | 1 |
| Akpek, EK; Gire, AI; Ingrodi, SM; Karakus, S | 1 |
| Kim, MK; Kim, YJ; Ko, JH; Lee, HJ; Oh, JY; Park, SY; Ryu, JS; Wee, WR | 1 |
| Bron, AM; Creuzot-Garcher, C; Muselier-Mathieu, A; Straub, M | 1 |
| Marshall, LL; Roach, JM | 1 |
| Kedzior, S; Muirhead, B; Prosperi-Porta, G; Sheardown, H | 1 |
| Borderie, V; Bouheraoua, N; Labbé, A; Laroche, L; Levy, O | 1 |
| Kilic, S; Kulualp, K | 1 |
| Al-Saedi, ZH; Alzhrani, RM; Boddu, SH | 1 |
| Gregory, DG | 1 |
| Cha, KH; Cho, W; Hwang, SJ; Hyun, SM; Kang, H; Park, HJ; Park, J; Sun, BK | 1 |
| Ahmad, A; Boyd, S; Chang, CN; Dozois, MD; Gu, FX; Hileeto, D; Jones, LW; Liang, H; Liu, S; Ng, DL; Reyad, MM | 1 |
| Ding, J; Kam, WR; Liu, Y; Sullivan, DA | 1 |
| Chen, X; Hao, J; Wang, L; Yang, L | 1 |
| Antonelli, S; Barabino, S; Cimbolini, N; Daull, P; Feraille, L; Garrigue, JS; Mauro, V | 1 |
| Choi, CY; Kim, HS; Lee, HK; Park, Y; Song, JS; Yoon, KC | 1 |
| Braun, T; Gehlsen, U; Krösser, S; Notara, M; Steven, P | 1 |
| Adam, R; Akesbi, J; Moyal, L; Nordmann, JP; Rodallec, FT | 1 |
| Baudouin, C; Flamion, B; Leonardi, A | 1 |
| Hirmand, H; Lee, WB; McCord, CD; Somia, N | 1 |
| Donnenfeld, ED; Greenman, HE; Perry, AR; Perry, HD; Savage, HE; Solomon, R; Wittpenn, JR | 1 |
| Choi, JS; Joo, CK; Kim, EC | 1 |
| Foulks, GN | 3 |
| Ridder, WH | 1 |
| Brown, GC; Brown, HC; Brown, MM; Peet, J; Roth, Z | 1 |
| Akpek, EK; Gupta, A; Sadeghi, PB | 1 |
| Beuerman, RW; Murakami, A; Nguyen, DH; Toshida, H | 1 |
| Mircheff, AK; Samant, DM; Schechter, JE; Selvam, S; Song, SW; Stevenson, D; Thomas, PB; Trousdale, MD; Wang, Y; Yiu, SC; Zhu, Z | 1 |
| Guzey, M; Karaman, SK; Ordulu, F; Satici, A; Sezer, S | 1 |
| Scoper, SV; Sheppard, JD; Wertheimer, ML | 1 |
| Denoyer, A; Nochez, Y; Pisella, PJ | 1 |
| Abee, CR; Scammell, JG; Schuler, AM; Tustin, GT | 1 |
| Bozkurt, O; Guzey, M; Karaman, SK; Ozardali, I; Satici, A; Sezer, S | 1 |
| Byun, YJ; Kim, EK; Kim, SW; Kim, TI; Kwon, SM; Park, WC; Seo, KY | 1 |
| Ambrósio, R; Salomão, MQ; Wilson, SE | 1 |
| Asfuroğlu, E; Toker, E | 1 |
| Cury, DB; Moss, AC | 1 |
| Asbell, PA; Miller, KL; Mink, DR; Perry, HD; Pflugfelder, SC; Satram-Hoang, S; Walt, JG; Wilson, SE | 1 |
| Chauhan, A; Gupta, C | 2 |
| Rao, SN | 2 |
| Lam, PT; Tam, PM; Young, AL | 1 |
| Friedman, NJ | 1 |
| Donnenfeld, ED; McDonald, MB; Perry, HD; Roberts, CW; Solomon, R; Wittpenn, JR | 1 |
| Rosenfeld, SI | 1 |
| Alaníz-de la O, JF; Baiza-Durán, L; Hernández-Quintela, E; Lozano-Alcazar, J; Medrano-Palafox, J | 1 |
| Chen, M; Gong, L; He, J; Li, Y; Qu, J; Sun, X; Xie, H; Zhang, Y; Zou, L | 1 |
| Akpek, EK; Stern, M; Utine, CA | 1 |
| Can, I; Genç, I; Gönül, I; Gürdal, C; Saraç, O; Takmaz, T | 1 |
| Malta, JB; Mian, SI; Musch, DC; Rhoades, W; Shtein, RM; Soong, HK; Sugar, A | 1 |
| Gülbahçe, R; Hoşal, BM; Sahli, E; Ustün, H; Zilelioğlu, G | 1 |
| Sugar, J; Weisberg, MP | 1 |
| Samudre, S; Scoper, SV; Sheppard, JD | 1 |
| Aksungur, P; Demirbilek, M; Denkbaş, EB; Ludwig, A; Unlü, N; Vandervoort, J | 1 |
| Barsam, A; D'Aversa, G; Donnenfeld, ED; Perry, AR; Perry, HD; Su, MY; Wittpenn, JR | 1 |
| Cetin, EN; Demiryay, E; Yaylali, V; Yildirim, C | 1 |
| Byun, YS; Cho, K; Choi, JA; Joo, CK; Na, KS; Rho, CR | 1 |
| Behar-Cohen, F; Di Tommaso, C; El Zaoui, I; Furrer, P; Guillarme, D; Gurny, R; Kaufmann, B; Rodriguez-Aller, M; Rudaz, S; Stella, C; Valamanesh, F; Veuthey, JL | 1 |
| Berg, MS; Charoenrook, V; Comert, E; Crews, LA; de Araujo, AL; de la Paz, MF; Kosheleff, VP; Lemp, MA; Pepose, JS; Sönmez, B; Sullivan, BD | 1 |
| Duan, HC; Li, ZY; Liu, Z; Song, YY; Wan, PX; Wang, XR; Wang, ZC; Zhang, W | 1 |
| Foulks, GN; Klamerus, KJ; Li, JZ; Liew, SH; Nichols, KK; Zhang, M | 1 |
| Chauhan, SK; Dana, R; Dastjerdi, MH; Kodati, S; Okanobo, A | 1 |
| Cooper, SR; Huang, JF; Liew, SH; McDowell, M; Pickering, EH; Rittenhouse, KD; Sace, F; Yafawi, R; Zhang, M | 1 |
| Altinkaynak, H; Goker, Y; Kara, N; Yildirim, Y; Yuksel, K | 1 |
| Arheart, KL; Galor, A; Lam, BL; Lee, DJ; McClure, LA; McCollister, KE; Ocasio, M; Perez, VL; Zheng, DD | 1 |
| Bron, AJ; Foulks, GN; Holland, EJ; McDonald, MB; Nelson, JD; Nichols, KK | 1 |
| Bremond-Gignac, D; Gicquel, JJ | 1 |
| Mahawong, W; Prabhasawat, P; Tesavibul, N | 1 |
| Karnchanachetanee, C; Kasemson, S; Prabhasawat, P; Tesavibul, N | 1 |
| Hoehn, ME; Kelly, SR; Walton, RC; Wilson, MW | 1 |
| Cross, WD; Kozma, CM; Lay, LF; Walt, JG | 1 |
| Auw-Hädrich, C; Mittelviefhaus, H | 1 |
| Hirsch, JD | 1 |
| Donnenfeld, ED; Perry, HD | 2 |
| Ruprecht, KW; Schirra, F | 1 |
| Pflugfelder, SC | 2 |
| Collum, LM; O'Brien, PD | 1 |
| Kujawa, A; Rózycki, R | 2 |
| Acheampong, A; Tang-Liu, DD | 1 |
| Baiza-Durán, L; Cruz-Olmos, E; González, JR; Hernández-Santoyo, A; López-Sánchez, MI; Mondragón-Flores, R; Quintana-Hau, JD; Sánchez-Castellanos, V | 1 |
| Donnenfeld, ED; Greenman, HE; Perry, HD; Solomon, R | 1 |
| Barber, LD; Foulks, GN; Pflugfelder, SC; Tauber, J | 1 |
| Akpek, EK; Tatlipinar, S | 1 |
| Christensen, MT; Cohen, SM; Sall, KN; Stein, JM | 1 |
| Hom, MM | 1 |
| Schechter, BA | 1 |
| McDonald, MB; Salib, GM; Smolek, M | 1 |
| Perry, HD; Wilson, SE | 1 |
| Farjo, QA; Gupta, A; Lelli, GJ; Mian, SI; Musch, DC; Nairus, TM | 1 |
| Rao, RD; Rao, SN | 1 |
| Gause, A | 1 |
| Chiang, TH; Mansfield, JE; McMahon, JP; Simonyi, S; Walt, JG | 1 |
| Brazzo, BG; Carniglia, PE; Roberts, CW | 1 |
| Brown, SM | 1 |
| Gierek-Ciaciura, S; Mrukwa-Kominek, E; Rogowska-Godela, A | 1 |
| Dwedi, S; Jain, AK; Sood, A; Sukhija, J | 1 |
| Dogru, M; Fujishima, H; Igarashi, A; Kawai, M; Kujira, A; Ogawa, Y; Okada, N; Okamoto, S; Shimazaki, J; Tatematsu, Y; Tsubota, K; Uchino, M; Wang, Y | 1 |
| Kim, MK; Lee, HJ; Lee, JH; Moon, JW; Shin, KC; Wee, WR | 1 |
| Liu, B; McGwin, G; Owsley, C; Rosenstiel, C; Willen, CM | 1 |
| De Paiva, CS; Pflugfelder, SC; Stern, ME; Villarreal, AL | 1 |
| Fiscella, RG; Killian, TD; Lee, JT; Walt, JG | 1 |
| Lemp, MA | 1 |
| Mundorf, TK; Reis, BL; Sall, K; Stevenson, OD | 1 |
| Reis, BL; Stevenson, D; Tauber, J | 1 |
| Feuer, WJ; Ji, Z; Pflugfelder, SC; Reis, BL; Stern, M; Turner, K | 1 |
| Gipson, IK; Kunert, KS; Smith, JA; Stern, ME; Tisdale, AS | 1 |
| Gipson, IK; Kunert, KS; Tisdale, AS | 1 |
46 review(s) available for cyclosporine and Dry Eye Syndromes
| Article | Year |
|---|---|
The Effect of OTX-101 on Tear Production in Patients with Severe Tear-deficient Dry Eye Disease: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies.
Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclosporine; Dry Eye Syndromes; Humans; Keratoconjunctivitis Sicca; Ophthalmic Solutions; Randomized Controlled Trials as Topic; Tears | 2022 |
Matching-adjusted indirect comparison of phase 3 clinical trial outcomes: OC-01 (varenicline solution) nasal spray and cyclosporine a 0.05% ophthalmic emulsion for the treatment of dry eye disease.
Topics: Cyclosporine; Dry Eye Syndromes; Emulsions; Humans; Immunosuppressive Agents; Nasal Sprays; Ophthalmic Solutions; Tears; Treatment Outcome; Varenicline | 2022 |
Ciclosporin A Cationic Emulsion 0.1% for the Management of Dry Eye Disease: Facts That Matter for Eye-Care Providers.
Topics: Cations; Cyclosporine; Dry Eye Syndromes; Emulsions; Humans; Inflammation; Randomized Controlled Trials as Topic; Tears | 2023 |
Topical corticosteroids for dry eye.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Cataract; Child; Child, Preschool; Cyclosporine; Dry Eye Syndromes; Female; Glucocorticoids; Humans; Loteprednol Etabonate; Lubricant Eye Drops; Male; Randomized Controlled Trials as Topic; Tobramycin | 2022 |
Management of inflammation in dry eye disease: Recommendations from a European panel of experts.
Topics: Cyclosporine; Dry Eye Syndromes; Humans; Inflammation; Ophthalmic Solutions; Risk Factors; Tears | 2023 |
Topics: Adolescent; Adult; Animals; Asthma; Atrial Fibrillation; Autoantibodies; Biomarkers; Breast Neoplasms; Child; Conjunctivitis, Allergic; Cornea; COVID-19; Cyclosporine; Cytokines; Death, Sudden, Cardiac; Defibrillators, Implantable; Diet; Disease Models, Animal; Docetaxel; Double-Blind Method; Dry Eye Syndromes; Educational Status; Emulsions; Female; Fluorescein Angiography; Fluoresceins; Focus Groups; Heart Failure; Hemothorax; Humans; Inflammation; Keratoconus; Male; Meibomian Glands; Mice; Middle Aged; Multiple Sclerosis; Myocardial Infarction; Myocardium; Nerve Fibers; Nigeria; Obesity; Overweight; Pandemics; Primary Prevention; Prospective Studies; Qualitative Research; Registries; Retinal Ganglion Cells; Retinal Vessels; Schools; Sirolimus; Tertiary Care Centers; Th1 Cells; Th2 Cells; Tomography, Optical Coherence; Troponin I; Tumor Necrosis Factor-alpha; United States; Ventricular Remodeling | 2022 |
Topical cyclosporine A therapy for dry eye syndrome.
Topics: Cyclosporine; Dry Eye Syndromes; Humans; Lubricant Eye Drops; Randomized Controlled Trials as Topic | 2019 |
An Updated Systematic Review With Meta-Analysis Of Randomized Trials On Topical Cyclosporin A For Dry-Eye Disease.
Topics: Administration, Ophthalmic; Cyclosporine; Dry Eye Syndromes; Humans; Lubricant Eye Drops; Randomized Controlled Trials as Topic | 2020 |
The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options.
Topics: Administration, Topical; Clinical Decision-Making; Cyclosporine; Dry Eye Syndromes; Goblet Cells; Homeostasis; Humans; Immunologic Factors; Immunosuppressive Agents; Inflammation; Integrins; Intercellular Adhesion Molecule-1; Lacrimal Apparatus; Lymphocyte Function-Associated Antigen-1; Phenylalanine; Steroids; Sulfones; T-Lymphocytes; Tears | 2020 |
Loteprednol Etabonate for the Treatment of Dry Eye Disease.
Topics: Animals; Anti-Allergic Agents; Cyclosporine; Dry Eye Syndromes; Humans; Inflammation; Loteprednol Etabonate; Lubricant Eye Drops; Quality of Life | 2020 |
Cyclosporine Anionic and Cationic Ophthalmic Emulsions in Dry Eye Disease: A Literature Review.
Topics: Anions; Cations; Cyclosporine; Dry Eye Syndromes; Emulsions; Humans; Immunosuppressive Agents | 2021 |
A Comprehensive Review of the Clinical Trials Conducted for Dry Eye Disease and the Impact of the Vehicle Comparators in These Trials.
Topics: Administration, Ophthalmic; Clinical Trials as Topic; Cyclosporine; Dry Eye Syndromes; Emulsions; Humans; Ophthalmic Solutions; Pharmaceutical Vehicles; Phenylalanine; Sulfones | 2021 |
Sjogren's syndrome from the perspective of ophthalmology.
Topics: Administration, Ophthalmic; Cyclosporine; Dry Eye Syndromes; Fatty Acids, Omega-3; Glucocorticoids; Humans; Immunosuppressive Agents; Lubricant Eye Drops; Muscarinic Agonists; Ophthalmology; Phenylalanine; Pilocarpine; Punctal Plugs; Quinuclidines; Sjogren's Syndrome; Sulfones; Thiophenes | 2017 |
Gaps in Current Knowledge and Priorities for Future Research in Dry Eye.
Topics: Biomedical Research; Cyclosporine; Dietary Supplements; Dry Eye Syndromes; Fatty Acids, Omega-3; Health Knowledge, Attitudes, Practice; Humans; Lubricant Eye Drops; Ophthalmology | 2017 |
[Topical cyclosporine A and risk of ocular surface neoplasia].
Topics: Administration, Topical; Cyclosporine; Dry Eye Syndromes; Eye Neoplasms; Humans; Ophthalmic Solutions; Risk Factors | 2018 |
Evaluating the novel application of cyclosporine 0.1% in ocular surface disease.
Topics: Conjunctivitis; Cyclosporine; Dry Eye Syndromes; Humans; Keratitis; Ophthalmic Solutions; Quality of Life; Severity of Illness Index; Tears; Treatment Outcome | 2018 |
Dry Eye Syndrome Preferred Practice Pattern®.
Topics: Academies and Institutes; Cyclosporine; Diagnostic Techniques, Ophthalmological; Dry Eye Syndromes; Humans; Immunosuppressive Agents; Ophthalmic Solutions; Ophthalmology; Phenylalanine; Physical Examination; Practice Patterns, Physicians'; Sulfones; United States | 2019 |
Ocular Pharmacokinetics of a Topical Ophthalmic Nanomicellar Solution of Cyclosporine (Cequa®) for Dry Eye Disease.
Topics: Administration, Ophthalmic; Clinical Trials, Phase III as Topic; Cyclosporine; Dry Eye Syndromes; Eye; Humans; Immunosuppressive Agents; Micelles; Nanoparticles; Ophthalmic Solutions; Treatment Outcome | 2019 |
Cyclosporine 0.09% solution (Cequa) for dry eye Disease.
Topics: Adult; Cyclosporine; Dry Eye Syndromes; Female; Humans; Ophthalmic Solutions; Pregnancy; Randomized Controlled Trials as Topic; Tears | 2019 |
Current treatment strategies for age-related ocular conditions.
Topics: Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Clinical Trials as Topic; Cyclosporine; Diabetes Mellitus; Diabetic Retinopathy; Disease Progression; Dry Eye Syndromes; Glaucoma; Glycated Hemoglobin; Humans; Macular Degeneration; Medication Adherence; Ophthalmic Solutions; Ophthalmologic Surgical Procedures; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2013 |
Managed care implications of age-related ocular conditions.
Topics: Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Clinical Trials as Topic; Cyclosporine; Diabetic Retinopathy; Drug Costs; Dry Eye Syndromes; Glaucoma, Open-Angle; Humans; Laser Therapy; Medicare; Medication Adherence; Ranibizumab; Severity of Illness Index; United States; Vascular Endothelial Growth Factor A; Vision Disorders; Wet Macular Degeneration | 2013 |
Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease.
Topics: Administration, Topical; Cyclosporine; Dry Eye Syndromes; Humans; Immunosuppressive Agents; Ophthalmic Solutions; Randomized Controlled Trials as Topic; Research Design | 2014 |
Topical cyclosporine A in the treatment of dry eye: a systematic review and meta-analysis.
Topics: Administration, Topical; Cyclosporine; Dry Eye Syndromes; Humans; Immunosuppressive Agents; Ophthalmic Solutions | 2014 |
Current options and emerging therapies for anterior ocular inflammatory disease.
Topics: Anti-Infective Agents; Antibodies, Monoclonal; Chemokine CCL11; Clinical Trials as Topic; Conjunctivitis, Allergic; Cyclosporine; Dibenzoxepins; Dry Eye Syndromes; Fluoroquinolones; Histamine H1 Antagonists; Humans; Immunotherapy; Levofloxacin; Moxifloxacin; Olopatadine Hydrochloride; Uveitis, Anterior | 2014 |
Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops in the Treatment of Dry Eye Syndrome: A Systematic Review and Meta-analysis.
Topics: Cyclosporine; Dose-Response Relationship, Drug; Dry Eye Syndromes; Humans; Immunosuppressive Agents; Ophthalmic Solutions; Treatment Outcome | 2015 |
A Pragmatic Approach to the Management of Dry Eye Disease: Evidence into Practice.
Topics: Cyclosporine; Dry Eye Syndromes; Evidence-Based Practice; Eyelid Diseases; Female; Humans; Immunosuppressive Agents; Lacrimal Apparatus; Lubricant Eye Drops; Meibomian Glands; Middle Aged; Precision Medicine; Quality of Life; Young Adult | 2015 |
Advances in the treatment of ocular dryness associated with Sjögren׳s syndrome.
Topics: Anti-Inflammatory Agents; Cyclosporine; Dry Eye Syndromes; Humans; Lubricant Eye Drops; Sjogren's Syndrome; Treatment Outcome | 2015 |
Treatment of Dry Eye Disease.
Topics: Cyclosporine; Dry Eye Syndromes; Humans; Immunosuppressive Agents; Lubricant Eye Drops; Nonprescription Drugs; Risk Factors | 2016 |
[Topical cyclosporine in ophthalmology: Pharmacology and clinical indications].
Topics: Administration, Topical; Cyclosporine; Dry Eye Syndromes; Eye Diseases; Humans; Immunosuppressive Agents; Ophthalmic Solutions | 2016 |
Keratitis in Dry Eye Disease and Topical Ciclosporin A.
Topics: Administration, Ophthalmic; Cyclosporine; Drug Approval; Dry Eye Syndromes; Emulsions; Humans; Immunosuppressive Agents; Keratitis; Ophthalmic Solutions; Pharmaceutical Preparations | 2017 |
Treatment of dry eye disease by the non-ophthalmologist.
Topics: Administration, Topical; Anti-Inflammatory Agents; Cyclosporine; Dry Eye Syndromes; Female; Humans; Lubricants; Male; Ophthalmic Solutions; Rheumatology; Risk Factors; Sjogren's Syndrome; Water-Electrolyte Balance | 2008 |
Impact of dry eye disease and treatment on quality of life.
Topics: Cellulose; Cyclosporine; Dry Eye Syndromes; Humans; Ophthalmic Solutions; Quality of Life | 2010 |
Evaluation and management of post-LASIK dry eye syndrome.
Topics: Cyclosporine; Dietary Supplements; Dry Eye Syndromes; Humans; Immunosuppressive Agents; Keratomileusis, Laser In Situ; Ophthalmic Solutions; Postoperative Care; Postoperative Complications; Risk Factors; Treatment Outcome | 2010 |
Clinical review: topical ophthalmic use of cyclosporin A.
Topics: Acute Disease; Blepharitis; Conjunctival Diseases; Conjunctivitis, Allergic; Corneal Transplantation; Cyclosporine; Dry Eye Syndromes; Emulsions; Eye Diseases; Graft Rejection; Graft vs Host Disease; Humans; Immunosuppressive Agents; Ophthalmic Solutions; Rosacea | 2010 |
[Dry eye. An update on epidemiology, diagnosis, therapy and new concepts].
Topics: Blinking; Combined Modality Therapy; Corneal Topography; Cyclosporine; Dry Eye Syndromes; Humans; Hyaluronic Acid; Interferometry; Ophthalmic Solutions; Palliative Care; Risk Factors; Sex Distribution; Treatment Outcome | 2004 |
Antiinflammatory therapy for dry eye.
Topics: Anti-Inflammatory Agents; Cyclosporine; Dacryocystitis; Dry Eye Syndromes; Humans; Immunosuppressive Agents; Keratoconjunctivitis Sicca | 2004 |
Dry eye: diagnosis and current treatment strategies.
Topics: Androgens; Anti-Inflammatory Agents; Cyclosporine; Dry Eye Syndromes; Humans; Hyaluronic Acid; Lacrimal Apparatus; Ophthalmic Solutions; Tears | 2004 |
Topical 0.05% cyclosporin in the treatment of dry eye.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials, Phase III as Topic; Cyclosporine; Dry Eye Syndromes; Emulsions; Humans; Immunosuppressive Agents; Ophthalmic Solutions | 2004 |
Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye.
Topics: Animals; Chemical Phenomena; Chemistry, Physical; Cyclosporine; Dry Eye Syndromes; Eye; Humans; Immunosuppressive Agents | 2005 |
Topical ciclosporin in the treatment of ocular surface disorders.
Topics: Conjunctivitis; Cyclosporine; Dry Eye Syndromes; Eye Diseases; Humans; Immunosuppressive Agents; Keratitis; Keratoconjunctivitis; Lichen Planus; Ophthalmic Solutions | 2005 |
Integrating restasis into the management of dry eye.
Topics: Cyclosporine; Dry Eye Syndromes; Humans; Immunosuppressive Agents; Ophthalmic Solutions; Treatment Outcome | 2006 |
Topical cyclosporine for treatment of ocular surface disease.
Topics: Animals; Apoptosis; Cyclosporine; Dry Eye Syndromes; Humans; Immunosuppressive Agents; Ophthalmic Solutions; Treatment Outcome | 2006 |
Drugs for some common eye disorders.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Anti-Bacterial Agents; Antioxidants; Carbonic Anhydrase Inhibitors; Cholinergic Agonists; Conjunctivitis, Allergic; Conjunctivitis, Bacterial; Cyclosporine; Diuretics, Osmotic; Dry Eye Syndromes; Eye Diseases; Glaucoma; Glucocorticoids; Humans; Immunosuppressive Agents; Macular Degeneration; Ophthalmic Solutions; Patient Compliance; Patient Selection; Photochemotherapy; Prostaglandins; Treatment Outcome; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Zinc | 2007 |
[Effect of anti-inflammatory therapy on the treatment of dry eye syndrome].
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Cyclosporine; Dry Eye Syndromes; Glucocorticoids; Humans; Immunosuppressive Agents; Tetracycline; Treatment Outcome | 2007 |
Pharmacological management of dry eye in the elderly patient.
Topics: Aged; Anti-Inflammatory Agents; Cyclosporine; Dry Eye Syndromes; Fatty Acids, Essential; Glucocorticoids; Humans; Inflammation; Lubrication; Ophthalmic Solutions; Serum | 2008 |
Management of dry eye disease.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents; Cyclosporine; Dry Eye Syndromes; Fatty Acids; Humans; Hygiene; Immunosuppressive Agents; Ophthalmic Solutions; Randomized Controlled Trials as Topic; Tetracycline; Vitamin A | 2008 |
68 trial(s) available for cyclosporine and Dry Eye Syndromes
| Article | Year |
|---|---|
A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 ESSENCE Study.
Topics: Administration, Ophthalmic; Adolescent; Adult; Aged; Aged, 80 and over; Conjunctiva; Cornea; Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Female; Fluorescein; Fluorescent Dyes; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Prospective Studies; Staining and Labeling; Treatment Outcome; Water | 2021 |
Efficacy of a 0.05% cyclosporine a topical nanoemulsion in dry eyes with obstructive meibomian gland dysfunction.
Topics: Cyclosporine; Dry Eye Syndromes; Eyelid Diseases; Humans; Hyaluronic Acid; Meibomian Gland Dysfunction; Meibomian Glands; Ophthalmic Solutions; Prospective Studies; Tears | 2022 |
Evaluation of the Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops (II) in the Treatment of Dry Eye Associated with Primary Sjögren's Syndrome.
Topics: Cyclosporine; Dry Eye Syndromes; Humans; Lubricant Eye Drops; Ophthalmic Solutions; Sjogren's Syndrome; Tears | 2023 |
Cyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Multicenter, Randomized, Double-Masked, Phase III, COSMO Trial.
Topics: Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Fluorescein; Gels; Humans; Immunosuppressive Agents; Ophthalmic Solutions; Tears; Treatment Outcome | 2022 |
Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials.
Topics: Adolescent; Child; Conjunctivitis, Allergic; Corneal Injuries; Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Emulsions; Humans; Immunosuppressive Agents; Ophthalmic Solutions; Treatment Outcome | 2023 |
Impact of Topical Cyclosporine-A or Topical Chloroquine on Post-LASIK Ocular Surface Stability - A Randomized Controlled Trial.
Topics: Cornea; Cyclosporine; Dry Eye Syndromes; Humans; Keratomileusis, Laser In Situ; Matrix Metalloproteinase 9; Tears; Visual Acuity | 2023 |
Efficacy and safety of 0.05% micellar nano-particulate (MNP) cyclosporine ophthalmic emulsion in the treatment of moderate-to-severe keratoconjunctivitis sicca: a 12-week, multicenter, randomized, active-controlled trial.
Topics: Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Emulsions; Humans; Keratoconjunctivitis Sicca; Micelles; Ophthalmic Solutions; Tears; Treatment Outcome | 2023 |
Proteomic analysis of tears in dry eye disease: A prospective, double-blind multicenter study.
Topics: Aryldialkylphosphatase; Biomarkers; Corneal Ulcer; Cyclosporine; Dry Eye Syndromes; Humans; Prospective Studies; Proteomics; rap GTP-Binding Proteins; Retinol-Binding Proteins, Plasma | 2023 |
Safety, adherence and discontinuation in varenicline solution nasal spray clinical trials for dry eye disease.
Topics: Cyclosporine; Dry Eye Syndromes; Humans; Nasal Sprays; Ophthalmic Solutions; Treatment Outcome; Varenicline | 2023 |
Topics: Adolescent; Adult; Animals; Asthma; Atrial Fibrillation; Autoantibodies; Biomarkers; Breast Neoplasms; Child; Conjunctivitis, Allergic; Cornea; COVID-19; Cyclosporine; Cytokines; Death, Sudden, Cardiac; Defibrillators, Implantable; Diet; Disease Models, Animal; Docetaxel; Double-Blind Method; Dry Eye Syndromes; Educational Status; Emulsions; Female; Fluorescein Angiography; Fluoresceins; Focus Groups; Heart Failure; Hemothorax; Humans; Inflammation; Keratoconus; Male; Meibomian Glands; Mice; Middle Aged; Multiple Sclerosis; Myocardial Infarction; Myocardium; Nerve Fibers; Nigeria; Obesity; Overweight; Pandemics; Primary Prevention; Prospective Studies; Qualitative Research; Registries; Retinal Ganglion Cells; Retinal Vessels; Schools; Sirolimus; Tertiary Care Centers; Th1 Cells; Th2 Cells; Tomography, Optical Coherence; Troponin I; Tumor Necrosis Factor-alpha; United States; Ventricular Remodeling | 2022 |
Safety and efficacy of cyclosporine (0.05% versus 0.09%) in dry eye disease. Is it the strength of cyclosporin that really matters?
Topics: Conjunctiva; Cyclosporine; Dry Eye Syndromes; Fluorescein; Humans | 2022 |
A randomized controlled trial involving college student: Comparing 0.15% hyaluronic acid with 0.05% cyclosporine A and 3% diquafosol sodium in the Treatment of Dry Eye.
Topics: Cyclosporine; Dry Eye Syndromes; Humans; Hyaluronic Acid; Prospective Studies | 2023 |
Changes in Human Tear Proteome Following Topical Treatment of Dry Eye Disease: Cyclosporine A Versus Diquafosol Tetrasodium.
Topics: Administration, Topical; Conjunctiva; Cornea; Cyclosporine; Dose-Response Relationship, Drug; Dry Eye Syndromes; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Prospective Studies; Proteome; Single-Blind Method; Tears; Treatment Outcome; Uracil Nucleotides | 2019 |
A prospective study to assess the role of vitamin D individually and in combination with cyclosporine in the treatment of dry eye in patients with deficient serum 25(OH)D levels.
Topics: Cyclosporine; Dry Eye Syndromes; Humans; Prospective Studies; Tears; Vitamin D | 2020 |
Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to Sjogren syndrome.
Topics: Cyclosporine; Dry Eye Syndromes; Humans; Lubricant Eye Drops; Ophthalmic Solutions; Prospective Studies; Sjogren's Syndrome; Tacrolimus; Tears | 2022 |
Efficacy, Safety, and Tolerability of a Novel Cyclosporine, a Formulation for Dry Eye Disease: A Multicenter Phase II Clinical Study.
Topics: Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Humans; Ophthalmic Solutions; Single-Blind Method; Treatment Outcome | 2021 |
A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye.
Topics: Adult; Aged; Aged, 80 and over; Cyclosporine; Dose-Response Relationship, Drug; Double-Blind Method; Dry Eye Syndromes; Emulsions; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Severity of Illness Index; Treatment Outcome; Young Adult | 2017 |
One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.
Topics: Adult; Aged; Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Emulsions; Female; Fluorescein; Humans; Immunosuppressive Agents; Keratitis; Male; Middle Aged; Ophthalmic Solutions; Tears | 2017 |
Evaluation of Clinical Efficacy and Safety of a Novel Cyclosporin A Nanoemulsion in the Treatment of Dry Eye Syndrome.
Topics: Administration, Ophthalmic; Adult; Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Emulsions; Female; Fluorophotometry; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Quality of Life; Tears; Treatment Outcome; Visual Acuity | 2017 |
[Prospective, monocentric, uncontrolled study of efficacy, tolerance and adherence of cyclosporin 0.1 % for severe dry eye syndrome].
Topics: Adult; Aged; Aged, 80 and over; Cyclosporine; Dose-Response Relationship, Drug; Dry Eye Syndromes; Eye Diseases; Female; Humans; Lubricant Eye Drops; Male; Middle Aged; Patient Compliance; Quality of Life; Severity of Illness Index; Sjogren's Syndrome; Tears; Treatment Outcome; Young Adult | 2018 |
Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies.
Topics: Aged; Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Logistic Models; Male; Middle Aged; Ophthalmic Solutions; Visual Acuity | 2019 |
Topical Cyclosporine Pretreatment of Ocular Surface in Allogeneic Hematopoietic Stem Cell Transplant Recipients.
Topics: Administration, Topical; Adolescent; Adult; Cyclosporine; Dry Eye Syndromes; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Ophthalmic Solutions; Prospective Studies; Transplantation, Homologous; Young Adult | 2018 |
Persistence of Efficacy of 0.1% Cyclosporin A Cationic Emulsion in Subjects with Severe Keratitis Due to Dry Eye Disease: A Nonrandomized, Open-label Extension of the SANSIKA Study.
Topics: Adult; Aged; Aged, 80 and over; Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Emulsions; Female; Follow-Up Studies; Humans; Keratitis; Male; Middle Aged; Ophthalmic Solutions; Tears; Treatment Outcome; Young Adult | 2018 |
A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
Topics: Administration, Ophthalmic; Aged; Cornea; Cyclosporine; Double-Blind Method; Drug Compounding; Dry Eye Syndromes; Female; Fluorescein; Fluorescent Dyes; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Quality of Life; Sickness Impact Profile; Tears; Treatment Outcome; Visual Analog Scale | 2019 |
A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
Topics: Administration, Ophthalmic; Adolescent; Adult; Aged; Aged, 80 and over; Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Intraocular Pressure; Male; Middle Aged; Ophthalmic Solutions; Surveys and Questionnaires; Tears; Treatment Outcome; Visual Acuity; Young Adult | 2019 |
Evaluation of the Efficacy and Safety of A Novel 0.05% Cyclosporin A Topical Nanoemulsion in Primary Sjögren's Syndrome Dry Eye.
Topics: Administration, Topical; Cell Count; Conjunctiva; Cyclosporine; Dose-Response Relationship, Drug; Double-Blind Method; Dry Eye Syndromes; Emulsions; Female; Follow-Up Studies; Goblet Cells; Humans; Middle Aged; Nanoparticles; Prospective Studies; Sjogren's Syndrome; Treatment Outcome | 2020 |
Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Conjunctiva; Cyclosporine; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Lubricant Eye Drops; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Prospective Studies; Tears; Uracil Nucleotides; Young Adult | 2019 |
Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: A 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study.
Topics: Adult; China; Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Female; Humans; Male; Middle Aged; Ophthalmic Solutions; Severity of Illness Index; Treatment Outcome | 2019 |
Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye.
Topics: Administration, Topical; Adult; Cyclosporine; Dose-Response Relationship, Drug; Dry Eye Syndromes; Emulsions; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Nanotechnology; Polyphosphates; Prospective Studies; Single-Blind Method; Tears; Treatment Outcome; Uracil Nucleotides | 2019 |
The effect of topical cyclosporine 0.05% on dry eye after cataract surgery.
Topics: Aged; Aged, 80 and over; Cataract Extraction; Cyclosporine; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Postoperative Complications; Treatment Outcome | 2013 |
Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Androstadienes; Anti-Allergic Agents; Cyclosporine; Double-Blind Method; Drug Therapy, Combination; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Loteprednol Etabonate; Male; Middle Aged; Ophthalmic Solutions; Prospective Studies; Visual Acuity | 2014 |
Prospective Randomized Trial Comparing Efficacy of Topical Loteprednol Etabonate 0.5% Versus Cyclosporine-A 0.05% for Treatment of Dry Eye Syndrome Following Hematopoietic Stem Cell Transplantation.
Topics: Administration, Topical; Adult; Aged; Anti-Allergic Agents; Cyclosporine; Dry Eye Syndromes; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Intraocular Pressure; Loteprednol Etabonate; Male; Middle Aged; Ophthalmic Solutions; Osmolar Concentration; Prospective Studies; Tears; Treatment Outcome; Visual Acuity; Young Adult | 2015 |
Long-term outcome after topical ciclosporin in severe dry eye disease with a 10-year follow-up.
Topics: Aged; Cornea; Cyclosporine; Dose-Response Relationship, Drug; Dry Eye Syndromes; Female; Follow-Up Studies; Forecasting; Humans; Immunosuppressive Agents; Male; Microscopy, Acoustic; Middle Aged; Ophthalmic Solutions; Retrospective Studies; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2016 |
Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Emulsions; Female; Fluorophotometry; Humans; Immunosuppressive Agents; Male; Middle Aged; Tears; Treatment Outcome; Young Adult | 2016 |
Proper balance of omega-3 and omega-6 fatty acid supplements with topical cyclosporine attenuated contact lens-related dry eye syndrome.
Topics: Administration, Ophthalmic; Administration, Oral; Adult; Contact Lenses; Cyclosporine; Cytokines; Dietary Supplements; Double-Blind Method; Drug Therapy, Combination; Dry Eye Syndromes; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Female; Humans; Male; Ophthalmic Solutions; Tears | 2016 |
A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye.
Topics: Adult; Cyclosporine; Dose-Response Relationship, Drug; Dry Eye Syndromes; Female; Humans; Hyaluronic Acid; Male; Middle Aged; Ophthalmic Solutions | 2017 |
A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome.
Topics: Adult; Cell Count; Conjunctiva; Cyclosporine; Diterpenes; Dry Eye Syndromes; Female; Fluorescein Angiography; Goblet Cells; Humans; Male; Ophthalmic Solutions; Prospective Studies; Retinyl Esters; Treatment Outcome; Vision Disorders; Vitamin A | 2009 |
Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome.
Topics: Administration, Topical; Cost of Illness; Cost-Benefit Analysis; Cyclosporine; Dry Eye Syndromes; Emulsions; Evidence-Based Medicine; Health Care Costs; Humans; Immunosuppressive Agents; Insurance, Health, Reimbursement; Life Expectancy; Quality of Life; Quality-Adjusted Life Years; Treatment Outcome | 2009 |
Dry eye associated with laser in situ keratomileusis: Mechanical microkeratome versus femtosecond laser.
Topics: Adult; Aged; Corneal Stroma; Cyclosporine; Dry Eye Syndromes; Humans; Immunosuppressive Agents; Incidence; Infant; Keratomileusis, Laser In Situ; Lasers, Excimer; Male; Middle Aged; Myopia; Surgical Flaps; Young Adult | 2009 |
Topical cyclosporine 0.05% for the prevention of dry eye disease progression.
Topics: Administration, Topical; Adult; Cell Count; Cyclosporine; Disease Progression; Dry Eye Syndromes; Female; Follow-Up Studies; Goblet Cells; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Prognosis; Prospective Studies | 2010 |
Cyclosporine 0.05% to improve visual outcomes after multifocal intraocular lens implantation.
Topics: Administration, Topical; Aged; Contrast Sensitivity; Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Lens Implantation, Intraocular; Male; Middle Aged; Phacoemulsification; Prospective Studies; Treatment Outcome; Visual Acuity | 2010 |
A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome.
Topics: Aged; Cyclosporine; Drug Carriers; Dry Eye Syndromes; Female; Humans; Male; Middle Aged; Ophthalmic Solutions; Treatment Outcome | 2010 |
A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
Topics: Adult; Conjunctival Diseases; Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Emulsions; Female; Humans; Intraocular Pressure; Male; Middle Aged; Ophthalmic Solutions; Pharmaceutical Vehicles; Treatment Outcome; Visual Acuity | 2010 |
The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Cyclosporine; Dry Eye Syndromes; Emulsions; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Prospective Studies; Single-Blind Method; Tears; Treatment Outcome | 2011 |
Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome.
Topics: Administration, Topical; Adolescent; Adult; Aged; Cell Count; Conjunctiva; Cyclosporine; Dry Eye Syndromes; Female; Follow-Up Studies; Goblet Cells; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Tears; Young Adult | 2011 |
Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal.
Topics: Cell Count; Cyclosporine; Disease Progression; Drug Administration Schedule; Dry Eye Syndromes; Female; Goblet Cells; Humans; Immunosuppressive Agents; Longitudinal Studies; Male; Middle Aged; Ophthalmic Solutions; Prospective Studies; Severity of Illness Index; Single-Blind Method; Substance Withdrawal Syndrome | 2011 |
[Study on the treatment of dry eye with Loteprednol Etabonate].
Topics: Adult; Androstadienes; Cyclosporine; Dry Eye Syndromes; Female; Humans; Loteprednol Etabonate; Male; Middle Aged; Treatment Outcome; Young Adult | 2012 |
Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
Topics: Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Female; Humans; Janus Kinase 3; Male; Middle Aged; Ophthalmic Solutions; Piperidines; Prospective Studies; Pyrimidines; Pyrroles; Surveys and Questionnaires; Tears; Treatment Outcome | 2012 |
Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease.
Topics: Administration, Topical; Conjunctiva; Cyclosporine; Cytokines; Dry Eye Syndromes; Female; Flow Cytometry; HLA-DR1 Antigen; Humans; Janus Kinase 3; Male; Middle Aged; Ophthalmic Solutions; Piperidines; Pyrimidines; Pyrroles; Tears | 2012 |
Evaluation of corneal morphologic and functional parameters after use of topical cyclosporine-a 0.05% in dry eye.
Topics: Administration, Ophthalmic; Adult; Cornea; Corneal Pachymetry; Cyclosporine; Dry Eye Syndromes; Endothelium, Corneal; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Prospective Studies; Tears; Time Factors; Treatment Outcome | 2012 |
A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction.
Topics: Administration, Topical; Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Emulsions; Eyelid Diseases; Female; Fluorescein; Humans; Immunosuppressive Agents; Male; Meibomian Glands; Middle Aged; Ophthalmic Solutions; Prospective Studies; Rose Bengal; Staining and Labeling; Tears; Treatment Outcome | 2012 |
Efficacy of cyclosporine 0.05% eye drops in Stevens Johnson syndrome with chronic dry eye.
Topics: Administration, Ophthalmic; Adult; Aged; Aged, 80 and over; Cyclosporine; Dry Eye Syndromes; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Prospective Studies; Stevens-Johnson Syndrome; Time Factors; Treatment Outcome; Young Adult | 2013 |
[Immunological phenomenons in the pathology of the tear film. Is cyclosporine the turn point in the Sjögren's syndrome treatment? Preliminary report].
Topics: Cyclosporine; Drug Administration Schedule; Dry Eye Syndromes; Female; Humans; Male; Middle Aged; Sjogren's Syndrome; Tears | 2004 |
Characterization of the novel ophthalmic drug carrier Sophisen in two of its derivatives: 3A Ofteno and Modusik-A Ofteno.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chromatography, High Pressure Liquid; Cyclosporine; Diclofenac; Drug Carriers; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Ophthalmic Solutions; Rabbits | 2005 |
Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
Topics: Adult; Aged; Aged, 80 and over; Cyclosporine; Drug Evaluation; Dry Eye Syndromes; Emulsions; Female; Humans; Immunosuppressive Agents; Intraocular Pressure; Male; Middle Aged; Ophthalmic Solutions; Safety; Tears; Treatment Outcome; Visual Acuity | 2005 |
An evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eye.
Topics: Adult; Cyclosporine; Drug Therapy, Combination; Dry Eye Syndromes; Emulsions; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Patient Satisfaction; Single-Blind Method; Treatment Outcome | 2006 |
Use of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patients.
Topics: Adult; Contact Lenses; Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Emulsions; Humans; Immunosuppressive Agents; Ophthalmic Solutions; Pilot Projects | 2006 |
Ketorolac during the induction phase of cyclosporin-A therapy.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclosporine; Drug Therapy, Combination; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Ketorolac; Male; Treatment Outcome | 2006 |
Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis.
Topics: Administration, Topical; Adult; Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Keratomileusis, Laser In Situ; Male; Middle Aged; Myopia; Ophthalmic Solutions; Postoperative Complications; Preservatives, Pharmaceutical; Prospective Studies; Refraction, Ocular; Tears; Treatment Outcome; Visual Acuity | 2006 |
Efficacy of topical cyclosporine 0.05% in the treatment of dry eye associated with graft versus host disease.
Topics: Administration, Topical; Adult; Cyclosporine; Dry Eye Syndromes; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Muramidase; Prospective Studies; Surveys and Questionnaires; Tears; Treatment Outcome; Visual Acuity | 2006 |
Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye.
Topics: Administration, Topical; Adult; Combined Modality Therapy; Cyclosporine; Dry Eye Syndromes; Eyelids; Female; Fluorescent Dyes; Humans; Lacrimal Apparatus; Male; Middle Aged; Prospective Studies; Prostheses and Implants; Rose Bengal; Tears; Treatment Outcome | 2007 |
Effect of topical cyclosporine on tear functions in tear-deficient dry eyes.
Topics: Administration, Topical; Adult; Cross-Over Studies; Cyclosporine; Dry Eye Syndromes; Female; Humans; Lacrimal Apparatus Diseases; Male; Middle Aged; Prospective Studies; Tears | 2007 |
Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Chronic Disease; Conjunctiva; Cornea; Cyclosporine; Dry Eye Syndromes; Female; Goblet Cells; Graft vs Host Disease; Humans; Male; Middle Aged; Mucin 5AC; Mucins; Ophthalmic Solutions; Patient Satisfaction; Pilot Projects; Tears; Treatment Outcome | 2008 |
Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes.
Topics: Adult; Contact Lenses; Cyclosporine; Dose-Response Relationship, Drug; Double-Blind Method; Dry Eye Syndromes; Emulsions; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Ophthalmic Solutions; Quality of Life; Treatment Outcome | 2008 |
Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
Topics: Cornea; Cyclosporine; Double-Blind Method; Drug Evaluation; Dry Eye Syndromes; Emulsions; Female; Humans; Intraocular Pressure; Male; Middle Aged; Ophthalmic Solutions; Safety; Tears; Visual Acuity | 2000 |
Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group.
Topics: Adult; Aged; Aged, 80 and over; Cyclosporine; Dose-Response Relationship, Drug; Double-Blind Method; Dry Eye Syndromes; Emulsions; Female; Humans; Intraocular Pressure; Male; Middle Aged; Ophthalmic Solutions; Safety; Tears; Visual Acuity | 2000 |
Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion.
Topics: Administration, Topical; Biomarkers; Conjunctiva; Cyclosporine; DNA Primers; Double-Blind Method; Dry Eye Syndromes; Emulsions; Epithelium; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Immunosuppressive Agents; Interleukin-6; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2000 |
Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antigens, CD; Biopsy; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Conjunctiva; Cyclosporine; Dry Eye Syndromes; Female; Fluorescent Antibody Technique, Indirect; HLA-DR Antigens; Humans; Immunophenotyping; Immunosuppressive Agents; Lymphocyte Activation; Lymphocytes; Male; Middle Aged; Ophthalmic Solutions; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Helper-Inducer | 2000 |
133 other study(ies) available for cyclosporine and Dry Eye Syndromes
| Article | Year |
|---|---|
Effect of Face Mask on Tear Film Stability in Eyes With Moderate-to-Severe Dry Eye Disease.
Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Cyclosporine; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Lubricant Eye Drops; Male; Masks; Middle Aged; Slit Lamp Microscopy; Tears; Visual Acuity | 2021 |
A hybrid ocular delivery system of cyclosporine-A comprising nanomicelle-laden polymeric inserts with improved efficacy and tolerability.
Topics: Animals; Cyclosporine; Dry Eye Syndromes; Micelles; Polymers; Rabbits | 2021 |
Efficacy of topical cyclosporine 0.05% and osmoprotective lubricating eye drops in treating dry eye disease and inflammation.
Topics: Cyclosporine; Dry Eye Syndromes; Humans; Inflammation; Lubricant Eye Drops; Prospective Studies; Tears | 2021 |
The Link module of human TSG-6 (Link_TSG6) promotes wound healing, suppresses inflammation and improves glandular function in mouse models of Dry Eye Disease.
Topics: Animals; Cell Adhesion Molecules; Cyclosporine; Disease Models, Animal; Dry Eye Syndromes; Humans; Inflammation; Mice; Mice, Inbred NOD; Tears; Wound Healing | 2022 |
Alleviation of dry eye syndrome with one dose of antioxidant, anti-inflammatory, and mucoadhesive lysine-carbonized nanogels.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cyclosporine; Dry Eye Syndromes; Free Radicals; Lysine; Nanogels; Ophthalmic Solutions; Rabbits | 2022 |
Comparison of treatment effects between 4.9% N-acetyl-aspartyl glutamic acid and 0.05% cyclosporine A eye drops in dry eye patients.
Topics: Cyclosporine; Dry Eye Syndromes; Fluorescein; Glutamic Acid; Humans; Meibomian Gland Dysfunction; Meibomian Glands; Ophthalmic Solutions; Retrospective Studies; Tears | 2022 |
First Generic Cyclosporine Drops for Dry Eye.
Topics: Cyclosporine; Drugs, Generic; Dry Eye Syndromes; Humans; Immunosuppressive Agents; Ophthalmic Solutions | 2022 |
Oil-free eye drops containing Cyclosporine A/cyclodextrin/PVA supramolecular complex as a treatment modality for dry eye disease.
Topics: Animals; Chickens; Cornea; Cyclodextrins; Cyclosporine; Dry Eye Syndromes; Female; Fluorescein; Humans; Mice; Ophthalmic Solutions; Scopolamine Derivatives | 2022 |
A randomized multicenter evaluation of the efficacy of 0.15% hyaluronic acid versus 0.05% cyclosporine A in dry eye syndrome.
Topics: Cyclosporine; Dry Eye Syndromes; Humans; Hyaluronic Acid; Ophthalmic Solutions; Tears | 2022 |
Age-Related Differences in the Clinical Patterns of Ocular Graft-Versus-Host Disease.
Topics: Adolescent; Adult; Cross-Sectional Studies; Cyclosporine; Dry Eye Syndromes; Graft vs Host Disease; Humans; Lubricant Eye Drops | 2022 |
Cellulose Acetate Phthalate-Based pH-Responsive Cyclosporine A-Loaded Contact Lens for the Treatment of Dry Eye.
Topics: Contact Lenses; Cyclosporine; Dry Eye Syndromes; Humans; Hydrogen-Ion Concentration; Ophthalmic Solutions; Tears | 2023 |
Cyclosporin A improves the hyperosmotic response in an experimental dry eye model by inhibiting the HMGB1/TLR4/NF-κB signaling pathway.
Topics: Animals; Cyclosporine; Dry Eye Syndromes; HMGB1 Protein; Humans; Inflammation; Mice; NF-kappa B; Signal Transduction; Toll-Like Receptor 4 | 2023 |
Comparison of Subjective Responses to Cyclosporine 0.05% Versus Lifitegrast 5.0% in Individuals With Dry Eye Disease.
Topics: Aged; Cyclosporine; Dry Eye Syndromes; Female; Humans; Male; Middle Aged; Ophthalmic Solutions; Sulfones | 2024 |
Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial.
Topics: Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Female; Fluorescein; Humans; Lubricant Eye Drops; Male; Middle Aged; Ophthalmic Solutions; Quality of Life; Tears; Treatment Outcome | 2023 |
In situ formation of injectable organogels for punctal occlusion and sustained release of therapeutics: design, preparation, in vitro and in vivo evaluation.
Topics: Cyclosporine; Delayed-Action Preparations; Dry Eye Syndromes; Humans; Lacrimal Apparatus; Ophthalmologic Surgical Procedures; Punctal Plugs | 2023 |
[Modern possibilities of pathogenetically oriented therapy for dry eye syndrome].
Topics: Conjunctiva; Conjunctivitis, Allergic; Corneal Diseases; Cyclosporine; Dry Eye Syndromes; Humans; Immunosuppressive Agents; Keratitis; Ophthalmic Solutions; Tears | 2023 |
Mucin-targeting-aptamer functionalized liposomes for delivery of cyclosporin A for dry eye diseases.
Topics: Animals; Cornea; Cyclosporine; Dry Eye Syndromes; Humans; Liposomes; Mucin-1; Mucins; Ophthalmic Solutions; Rats | 2023 |
Comparison of matrix metallopeptidase-9 expression following cyclosporine and diquafosol treatment in dry eye.
Topics: Cyclosporine; Dry Eye Syndromes; Humans; Matrix Metalloproteinase 9; Uracil Nucleotides | 2023 |
Bacillus-Derived Manganese Superoxide Dismutase Relieves Ocular-Surface Inflammation and Damage by Reducing Oxidative Stress and Apoptosis in Dry Eye.
Topics: Animals; Antioxidants; Apoptosis; Bacillus; Cyclosporine; Dry Eye Syndromes; Mice; Oxidative Stress; Reactive Oxygen Species; Superoxide Dismutase | 2023 |
Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis.
Topics: Anti-Inflammatory Agents; Cyclosporine; Dry Eye Syndromes; Emulsions; Humans; Longitudinal Studies; Ophthalmic Solutions; Retrospective Studies | 2023 |
Relationship between ocular surface temperature and 0.1% cyclosporine a in dry eye syndrome with meibomian gland dysfunction.
Topics: Cyclosporine; Dry Eye Syndromes; Humans; Meibomian Gland Dysfunction; Meibomian Glands; Retrospective Studies; Tears; Temperature | 2023 |
An amphipathic cell penetrating peptide aids cell penetration of cyclosporin A and increases its therapeutic effect in an in vivo mouse model for dry eye disease.
Topics: Animals; Cell Line; Cell-Penetrating Peptides; Cyclosporine; Disease Models, Animal; Drug Carriers; Dry Eye Syndromes; Epithelial Cells; Humans; Interleukin-6; Interleukin-8; Mice; Microscopy, Confocal; Solubility | 2019 |
Perfluorohexyloctane (F
Topics: Cyclosporine; Drug Carriers; Drug Delivery Systems; Dry Eye Syndromes; Fluorocarbons; Immunosuppressive Agents; Microscopy, Atomic Force; Particle Size; Spectrophotometry, Infrared; Surface Properties | 2019 |
Cyclosporine A eyedrops with self-nanoemulsifying drug delivery systems have improved physicochemical properties and efficacy against dry eye disease in a murine dry eye model.
Topics: Animals; Apoptosis; Cell Count; Conjunctiva; Cyclosporine; Cytokines; Disease Models, Animal; Drug Delivery Systems; Dry Eye Syndromes; Emulsions; Epithelium, Corneal; Fluorescein; Goblet Cells; Hydrogen-Ion Concentration; Inflammation; Ki-67 Antigen; Mice; Nanoparticles; Nephelometry and Turbidimetry; Ophthalmic Solutions; Particle Size; Tears; Treatment Outcome; Viscosity | 2019 |
Systematic Optimization, In Vitro Drug Release, and Preliminary Nonclinical Toxicity Assessment of Nonphospholipid-Based Topical Ophthalmic Emulsions Containing 0.05 or 0.1% w/w Cyclosporin A for Dry-Eye Syndrome Management.
Topics: Administration, Ophthalmic; Calcineurin Inhibitors; Cyclosporine; Drug Liberation; Dry Eye Syndromes; Emulsions; Humans; In Vitro Techniques; Particle Size | 2019 |
Protective Effects of Cyclosporine A Emulsion Versus Cyclosporine A Cationic Emulsion Against Desiccation Stress in Human Corneal Epithelial Cells.
Topics: Apoptosis; Cell Line; Cyclosporine; Desiccation; Dry Eye Syndromes; Emulsions; Epithelium, Corneal; Humans; Immunosuppressive Agents; Stress, Mechanical; Tears | 2020 |
Association of Killer Cell Immunoglobulin-like Receptor Genotypes and Haplotypes in Dry Eye Disease Patients Treated with Restasis and Systane.
Topics: Adult; Cyclosporine; DNA Primers; Dry Eye Syndromes; Female; Gene Frequency; Genotype; Genotyping Techniques; Haplotypes; Humans; Immunosuppressive Agents; Lubricant Eye Drops; Male; Middle Aged; Polymerase Chain Reaction; Receptors, KIR; Young Adult | 2021 |
Dry Eye Disease Practice in Ghana: Diagnostic Perspectives, Treatment Modalities, and Challenges.
Topics: Adult; Cyclosporine; Diagnostic Techniques, Ophthalmological; Dry Eye Syndromes; Female; Fluorescein; Fluorescent Dyes; Ghana; Humans; Immunosuppressive Agents; Lubricant Eye Drops; Male; Middle Aged; Optometrists; Osmolar Concentration; Practice Patterns, Physicians'; Punctal Plugs; Serum; Surveys and Questionnaires; Tears; Treatment Outcome; Young Adult | 2020 |
[Assessment of Langerhans Cells in the Central Cornea as Tool for Monitoring Inflammatory Changes in Patients with Keratoconjunctivitis sicca under Topical Therapy with Cyclosporine A 0.05% Eye Drops].
Topics: Cornea; Cyclosporine; Dry Eye Syndromes; Female; Humans; Keratoconjunctivitis Sicca; Langerhans Cells; Male; Ophthalmic Solutions; Prospective Studies; Quality of Life; Tears | 2020 |
Commentary: Dry eye syndrome and vitamin D deficiency.
Topics: Cyclosporine; Dry Eye Syndromes; Humans; Prospective Studies; Vitamin D; Vitamin D Deficiency | 2020 |
Tolerance and Adherence to Cationic 0.1% Cyclosporine in Ocular Graft-versus-Host Disease.
Topics: Adult; Aged; Aged, 80 and over; Cyclosporine; Dose-Response Relationship, Drug; Drug Tolerance; Dry Eye Syndromes; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Intraocular Pressure; Male; Medication Adherence; Middle Aged; Prognosis; Retrospective Studies; Young Adult | 2021 |
A Novel Eyes Topical Drug Delivery System: CsA-LNC for the Treatment of DED.
Topics: Administration, Ophthalmic; Animals; Biological Availability; Chromatography, High Pressure Liquid; Cyclosporine; Cytokines; Drug Delivery Systems; Dry Eye Syndromes; Irritants; Lipids; Male; Mass Spectrometry; Nanoparticles; Ophthalmic Solutions; Rabbits; Rats; Rats, Sprague-Dawley; Tears; Tissue Distribution | 2020 |
The use of topical cyclosporine A 0.05% as treatment for primary alacrimia in Allgrove syndrome.
Topics: Adrenal Insufficiency; Adult; Cyclosporine; Dry Eye Syndromes; Esophageal Achalasia; Humans; Male | 2022 |
[The value and application prospect of cyclosporine A in the treatment of dry eye].
Topics: Cyclosporine; Dry Eye Syndromes; Humans; Inflammation; Ophthalmic Solutions | 2020 |
Comparison of Treatment Effect and Tolerance of the Topical Application of Mizoribine and Cyclosporine A in a Mouse Dry Eye Model.
Topics: Animals; Cyclosporine; Dry Eye Syndromes; Mice; Mice, Inbred C57BL; Oregon; Ribonucleosides | 2020 |
Topical cyclosporine a (0.05%) treatment in dry eye patients: a comparison study of Sjogren's syndrome versus non-Sjogren's syndrome.
Topics: Cyclosporine; Dry Eye Syndromes; Humans; Retrospective Studies; Sjogren's Syndrome; Tears | 2021 |
Ocular surface response of two preservative-free cylcosporine A emulsion eye drops in a mouse model of dry eye.
Topics: Administration, Ophthalmic; Animals; Conjunctiva; Cornea; Cyclosporine; Disease Models, Animal; Dry Eye Syndromes; Emulsions; Eye Proteins; Female; Fluorophotometry; Immunosuppressive Agents; Lacrimal Apparatus; Mice; Mice, Inbred C57BL; Ophthalmic Solutions; Preservatives, Pharmaceutical; Tears; Transcriptome; Treatment Outcome | 2021 |
Real-world experience of using ciclosporin-A 0.1% in the management of ocular surface inflammatory diseases.
Topics: Adult; Aged; Cyclosporine; Dry Eye Syndromes; Female; Humans; Male; Middle Aged; Pemphigoid, Benign Mucous Membrane; Retrospective Studies; Stevens-Johnson Syndrome | 2022 |
Ocular Findings of Pediatric Dry Eye Related to Graft-Versus-Host Disease
Topics: Administration, Topical; Adolescent; Child; Child, Preschool; Conjunctiva; Cyclosporine; Dry Eye Syndromes; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Retrospective Studies; Tears; Transplantation, Homologous | 2021 |
Cytomegalovirus Anterior Uveitis Following Topical Cyclosporine A.
Topics: Administration, Ophthalmic; Aged; Antiviral Agents; Aqueous Humor; Cyclosporine; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Dry Eye Syndromes; Emulsions; Eye Infections, Viral; Female; Ganciclovir; Gene Dosage; Humans; Immunosuppressive Agents; Real-Time Polymerase Chain Reaction; Uveitis, Anterior; Valganciclovir | 2018 |
Patients' Perceived Treatment Effectiveness in Dry Eye Disease.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antidepressive Agents; Cross-Sectional Studies; Cyclosporine; Disability Evaluation; Doxycycline; Dry Eye Syndromes; Female; Fish Oils; Glucocorticoids; Humans; Immunosuppressive Agents; Linseed Oil; Male; Middle Aged; Patients; Serum; Sickness Impact Profile; Treatment Outcome; Young Adult | 2017 |
Anti-inflammatory effect of hydroxyproline-GQDGLAGPK in desiccation stress-induced experimental dry eye mouse.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Cyclosporine; Disease Models, Animal; Dry Eye Syndromes; Histocytochemistry; Hyaluronic Acid; Mice; Ophthalmic Solutions; Peptides; Polyphosphates; Treatment Outcome; Uracil Nucleotides | 2017 |
Concerns over Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.
Topics: Administration, Topical; Cyclosporine; Dry Eye Syndromes; Emulsions; Humans; Immunosuppressive Agents; Ophthalmic Solutions; Tears; Treatment Outcome | 2017 |
Author's Reply to: "Concerns Over: Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease".
Topics: Administration, Topical; Cyclosporine; Dry Eye Syndromes; Emulsions; Humans; Immunosuppressive Agents; Ophthalmic Solutions; Tears; Treatment Outcome | 2017 |
Adjunctive role of self-retained cryopreserved amniotic membrane in treating immune-related dry eye disease.
Topics: Amnion; Autoimmune Diseases; Cryopreservation; Cyclosporine; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Lubricant Eye Drops; Middle Aged; Visual Acuity | 2018 |
Comment on: 'Corneal confocal scanning laser microscopy in patients with dry eye disease treated with topical cyclosporine'.
Topics: Administration, Topical; Cornea; Cyclosporine; Dry Eye Syndromes; Humans; Immunosuppressive Agents; Microscopy, Confocal; Ophthalmic Solutions | 2018 |
Reply to Comment on: 'Corneal confocal scanning laser microscopy in patients with dry eye disease treated with topical cyclosporine'.
Topics: Administration, Topical; Cornea; Cyclosporine; Dry Eye Syndromes; Humans; Immunosuppressive Agents; Microscopy, Confocal; Ophthalmic Solutions | 2018 |
Improving the topical ocular pharmacokinetics of lyophilized cyclosporine A-loaded micelles: formulation, in vitro and in vivo studies.
Topics: Administration, Ophthalmic; Animals; Biological Availability; Cell Line; Cyclosporine; Delayed-Action Preparations; Drug Carriers; Drug Compounding; Drug Liberation; Drug Stability; Dry Eye Syndromes; Eye; Freeze Drying; Humans; Immunosuppressive Agents; Micelles; Polyesters; Polyethylene Glycols; Powders; Rabbits; Technology, Pharmaceutical; Tissue Distribution | 2018 |
RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model.
Topics: Animals; Conjunctiva; Cornea; Cyclosporine; Disease Models, Animal; Dry Eye Syndromes; Female; Goblet Cells; Humans; Inflammation Mediators; Lacrimal Apparatus; Male; Mice; Mice, Inbred NOD; Mucins; Ophthalmic Solutions; Phenylalanine; Polyphosphates; Prescription Drugs; Scopolamine; Sulfones; Tears; Thymosin; Treatment Outcome; Uracil Nucleotides | 2018 |
Comparison of 0.025% FK-506, 0.05% Cyclosporin A, and 0.3% Sodium Hyaluronate Eye Drops for the Treatment of Botulinum Toxin B-Induced Mouse Dry Eye.
Topics: Administration, Topical; Animals; Botulinum Toxins, Type A; Cyclosporine; Cytokines; Disease Models, Animal; Dry Eye Syndromes; Female; Hyaluronic Acid; Mice; Mice, Inbred CBA; Ophthalmic Solutions; Tears | 2018 |
Comorbidities and Prescribed Medications in Patients With or Without Dry Eye Disease: A Population-Based Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cataract; Comorbidity; Cyclosporine; Databases, Factual; Diabetes Mellitus, Type 2; Drug Prescriptions; Dry Eye Syndromes; Emulsions; Female; Glaucoma; Humans; Hypertension; Immunosuppressive Agents; International Classification of Diseases; Male; Middle Aged; Military Personnel; Ophthalmic Solutions; Retrospective Studies; Thyroid Diseases; United States | 2019 |
Comparison of Ocular Surface Mucin Expression After Topical Ophthalmic Drug Administration in Dry Eye-Induced Mouse Model.
Topics: Administration, Topical; Alanine; Animals; Anti-Inflammatory Agents; Cyclosporine; Disease Models, Animal; Dry Eye Syndromes; Epithelium, Corneal; Female; Inflammation; Mice; Mice, Inbred C57BL; Mucins; Ophthalmic Solutions; Polyphosphates; Quinolones; Uracil Nucleotides | 2018 |
Real-world experience at a Scottish university teaching hospital regarding the tolerability and persistence with topical Ciclosporin 0.1% (Ikervis) treatment in patients with dry eye disease.
Topics: Adult; Aged; Aged, 80 and over; Cyclosporine; Dry Eye Syndromes; Female; Hospitals, Teaching; Humans; Immunosuppressive Agents; Keratitis; Male; Middle Aged; Ophthalmic Solutions; Scotland; Young Adult | 2019 |
The Efficiency of Cyclosporine A-Eluting Contact Lenses for the Treatment of Dry Eye.
Topics: Animals; Cell Count; Chromatography, High Pressure Liquid; Conjunctiva; Contact Lenses, Hydrophilic; Cyclosporine; Cytokines; Disease Models, Animal; Drug Carriers; Dry Eye Syndromes; Enzyme-Linked Immunosorbent Assay; Female; Goblet Cells; Immunosuppressive Agents; Ophthalmic Solutions; Rabbits; Tears | 2019 |
Modulation of Inflammation-Related Genes in the Cornea of a Mouse Model of Dry Eye upon Treatment with Cyclosporine Eye Drops.
Topics: Administration, Ophthalmic; Animals; Cornea; Cyclosporine; Cytokines; Disease Models, Animal; Dry Eye Syndromes; Female; Fluorescein; Fluorescent Dyes; Gene Expression Regulation; Genetic Markers; Immunosuppressive Agents; Inflammation; Mice; Mice, Inbred C57BL; Ophthalmic Solutions; Receptors, Cytokine; RNA, Messenger; Tears | 2019 |
Ciclosporin eye drops (Ikervis°) and dry eye syndrome.
Topics: Cyclosporine; Dry Eye Syndromes; Eye Infections; Eye Neoplasms; Eye Pain; Humans; Immunosuppressive Agents | 2017 |
Cationized hyaluronic acid coated spanlastics for cyclosporine A ocular delivery: Prolonged ocular retention, enhanced corneal permeation and improved tear production.
Topics: Administration, Ophthalmic; Animals; Cations; Cyclosporine; Drug Liberation; Dry Eye Syndromes; Eye; Hexoses; Hyaluronic Acid; Immunosuppressive Agents; Liposomes; Male; Rabbits; Tears | 2019 |
Short-Term Effects of Ground-Level Ozone in Patients With Dry Eye Disease: A Prospective Clinical Study.
Topics: Adult; Aged; Cornea; Cross-Sectional Studies; Cyclosporine; Dry Eye Syndromes; Female; Fluorescein; Fluorescent Dyes; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Oxidants, Photochemical; Ozone; Polyphosphates; Prospective Studies; Tears; Uracil Nucleotides | 2019 |
A study of refractory cases of persistent epithelial defects associated with dry eye syndrome and recurrent corneal erosions successfully treated with cyclosporine A 0.05% eye drops.
Topics: Administration, Topical; Adult; Corneal Diseases; Cyclosporine; Dry Eye Syndromes; Epithelium, Corneal; Female; Humans; Male; Middle Aged; Ophthalmic Solutions; Particle Size; Retrospective Studies; Surface Properties | 2019 |
What is the value of incorporating tear osmolarity measurement in assessing patient response to therapy in dry eye disease?
Topics: Antirheumatic Agents; Blood; Cornea; Cyclosporine; Dry Eye Syndromes; Female; Fluorescein; Fluorescent Dyes; Fluorophotometry; Glucocorticoids; Humans; Immunosuppressive Agents; Interleukin 1 Receptor Antagonist Protein; Lubricants; Male; Middle Aged; Ophthalmic Solutions; Osmolar Concentration; Retrospective Studies; Surveys and Questionnaires; Tears | 2014 |
The efficacy of topical 0.05 % cyclosporine A in patients with dry eye disease associated with Sjögren's syndrome.
Topics: Administration, Topical; Adult; Case-Control Studies; Cyclosporine; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Prospective Studies; Sjogren's Syndrome | 2014 |
Topical cyclosporine: are all indications justified?
Topics: Cyclosporine; Dry Eye Syndromes; Humans; Immunosuppressive Agents; Ophthalmic Solutions | 2014 |
Current practice pattern for dry eye patients in South Korea: a multicenter study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Attitude of Health Personnel; Cross-Sectional Studies; Cyclosporine; Dry Eye Syndromes; Fatty Acids, Essential; Female; Humans; Lubricant Eye Drops; Male; Middle Aged; Ointments; Ophthalmology; Practice Guidelines as Topic; Professional Practice; Referral and Consultation; Republic of Korea; Severity of Illness Index; Young Adult | 2014 |
Short-term effects of topical cyclosporine A 0.05% (Restasis) in long-standing prosthetic eye wearers: a pilot study.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Cyclosporine; Dry Eye Syndromes; Eye, Artificial; Eyelids; Female; Fourier Analysis; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Pilot Projects; Prospective Studies; Tears; Time Factors; Tomography, Optical Coherence | 2014 |
Supercritical fluid-mediated liposomes containing cyclosporin A for the treatment of dry eye syndrome in a rabbit model: comparative study with the conventional cyclosporin A emulsion.
Topics: Animals; Blinking; Cyclosporine; Disease Models, Animal; Dry Eye Syndromes; Liposomes; Male; Models, Biological; Permeability; Rabbits; Tears | 2014 |
Topical cyclosporine a treatment in corneal refractive surgery and patients with dry eye.
Topics: Administration, Topical; Adolescent; Adult; Aged; Cyclosporine; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Keratomileusis, Laser In Situ; Male; Middle Aged; Ophthalmic Solutions; Photorefractive Keratectomy; Postoperative Period; Preoperative Period; Refractive Surgical Procedures; Retrospective Studies; Young Adult | 2014 |
Lower Lid Laxity is Negatively Correlated with Improvement of the Ocular Surface Disease Index in Dry Eye Treatment.
Topics: Corneal Diseases; Cyclosporine; Dry Eye Syndromes; Eyelids; Female; Fluorometholone; Glucocorticoids; Humans; Immunosuppressive Agents; Lubricant Eye Drops; Male; Middle Aged; Oculomotor Muscles; Surveys and Questionnaires; Tears | 2016 |
Thymosin β4 significantly reduces the signs of dryness in a murine controlled adverse environment model of experimental dry eye.
Topics: Administration, Topical; Animals; Cyclosporine; Disease Models, Animal; Dose-Response Relationship, Drug; Dry Eye Syndromes; Environment, Controlled; Female; Humans; Mice; Mice, Inbred C57BL; Ophthalmic Solutions; Thymosin; Wound Healing | 2015 |
Comparison of Topical Cyclosporine and Diquafosol Treatment in Dry Eye.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Cyclosporine; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Prospective Studies; Purinergic P2Y Receptor Agonists; Tears; Uracil Nucleotides | 2015 |
The course of dry eye after phacoemulsification surgery.
Topics: Aged; Aged, 80 and over; Chronic Disease; Cyclosporine; Dry Eye Syndromes; Female; Fluorescein; Fluorophotometry; Humans; Immunosuppressive Agents; Lubricant Eye Drops; Male; Middle Aged; Phacoemulsification; Retrospective Studies; Staining and Labeling; Tears | 2015 |
FTY720 ameliorates Dry Eye Disease in NOD mice: Involvement of leukocytes inhibition and goblet cells regeneration in ocular surface tissue.
Topics: Animals; Cell Count; Conjunctiva; Cyclosporine; Disease Models, Animal; Dry Eye Syndromes; Enzyme-Linked Immunosorbent Assay; Fingolimod Hydrochloride; Goblet Cells; Immunohistochemistry; Immunosuppressive Agents; Intercellular Adhesion Molecule-1; Interleukin-1beta; Lacrimal Apparatus; Leukocytes; Male; Mice; Mice, Inbred NOD; Real-Time Polymerase Chain Reaction; Regeneration; RNA, Messenger; Tears; Tumor Necrosis Factor-alpha | 2015 |
Isolated ocular lichen planus in a child.
Topics: Autoimmune Diseases; Child; Conjunctival Diseases; Cyclosporine; Drug Therapy, Combination; Dry Eye Syndromes; Female; Fibrinogen; Glucocorticoids; Humans; Immunosuppressive Agents; Lichen Planus; Methotrexate; Prednisolone | 2015 |
Cyclosporine for Dry Eye Associated With Nivolumab: A Case Progressing to Corneal Perforation.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Corneal Perforation; Cyclosporine; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Nivolumab; Treatment Outcome | 2016 |
Frequent Dosing of Topical Cyclosporine A for Severe Ocular Surface Disease.
Topics: Administration, Topical; Adolescent; Adult; Aged; Cyclosporine; Dose-Response Relationship, Drug; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Retrospective Studies; Young Adult | 2016 |
Comparison of Topical Application of TSG-6, Cyclosporine, and Prednisolone for Treating Dry Eye.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Cell Adhesion Molecules; Conjunctiva; Cornea; Cyclosporine; Cytokines; Disease Models, Animal; Dry Eye Syndromes; Female; Gene Expression Regulation; Immunosuppressive Agents; In Situ Nick-End Labeling; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Ophthalmic Solutions; Prednisolone; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Tears | 2016 |
Phenylboronic-Acid-Based Polymeric Micelles for Mucoadhesive Anterior Segment Ocular Drug Delivery.
Topics: Administration, Ophthalmic; Animals; Biocompatible Materials; Biological Availability; Boronic Acids; Cell Line; Cornea; Cyclosporine; Drug Delivery Systems; Drug Liberation; Dry Eye Syndromes; Humans; Micelles; Ophthalmic Solutions; Permeability; Rats; Rats, Sprague-Dawley; Surface Plasmon Resonance; Tears | 2016 |
Efficacy of Several Therapeutic Agents in a Murine Model of Dry Eye Syndrome.
Topics: Animals; Anti-Inflammatory Agents; Blinking; Cyclosporine; Diclofenac; Disease Models, Animal; Dry Eye Syndromes; Female; Mice; Mice, Inbred BALB C; Ophthalmic Solutions; Tears | 2016 |
Formulation and In Vitro Evaluation of Cyclosporine-A Inserts Prepared Using Hydroxypropyl Methylcellulose for Treating Dry Eye Disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cattle; Chemistry, Pharmaceutical; Cyclosporine; Drug Delivery Systems; Dry Eye Syndromes; Endothelium, Corneal; Humans; Hypromellose Derivatives; Polysaccharides, Bacterial | 2016 |
New Grading System and Treatment Guidelines for the Acute Ocular Manifestations of Stevens-Johnson Syndrome.
Topics: Acute Disease; Amnion; Anti-Bacterial Agents; Combined Modality Therapy; Cyclosporine; Dexamethasone; Dry Eye Syndromes; Eyelid Diseases; Female; Fluorophotometry; Fluoroquinolones; Glucocorticoids; Guidelines as Topic; Humans; Middle Aged; Moxifloxacin; Prospective Studies; Severity of Illness Index; Stevens-Johnson Syndrome; Tobramycin; Visual Acuity | 2016 |
Cyclosporine Amicellar delivery system for dry eyes.
Topics: Animals; Cell Count; Cell Shape; Conjunctiva; Cyclosporine; Drug Delivery Systems; Dry Eye Syndromes; Epithelial Cells; Female; Goblet Cells; Hydrogen-Ion Concentration; Immunosuppressive Agents; Male; Micelles; Ophthalmic Solutions; Osmolar Concentration; Particle Size; Rabbits; Tears; Temperature; Tissue Distribution | 2016 |
Prolonged Ocular Retention of Mucoadhesive Nanoparticle Eye Drop Formulation Enables Treatment of Eye Diseases Using Significantly Reduced Dosage.
Topics: Animals; Boronic Acids; Cyclosporine; Dry Eye Syndromes; Eye Diseases; Female; Male; Mice; Mice, Inbred C57BL; N-Acetylneuraminic Acid; Nanoparticles; Ophthalmic Solutions; Rabbits | 2016 |
Do Cyclosporine A, an IL-1 Receptor Antagonist, Uridine Triphosphate, Rebamipide, and/or Bimatoprost Regulate Human Meibomian Gland Epithelial Cells?
Topics: Alanine; Antihypertensive Agents; Antioxidants; Antirheumatic Agents; Bimatoprost; Cell Count; Cell Proliferation; Cell Survival; Cells, Cultured; Cyclosporine; Dry Eye Syndromes; Epithelial Cells; Humans; Immunosuppressive Agents; Interleukin 1 Receptor Antagonist Protein; Meibomian Glands; Quinolones; Signal Transduction; Uridine Triphosphate | 2016 |
Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye.
Topics: Administration, Topical; Animals; Cornea; Cyclosporine; Disease Models, Animal; Dry Eye Syndromes; Emulsions; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Tears; Treatment Outcome | 2016 |
A semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic option for topical treatment of dry eye.
Topics: Administration, Topical; Animals; Cell Count; Conjunctiva; Cyclosporine; Dexamethasone; Disease Models, Animal; Drug Carriers; Drug Therapy, Combination; Dry Eye Syndromes; Female; Flow Cytometry; Fluorocarbons; Glucocorticoids; Goblet Cells; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Ophthalmic Solutions; Treatment Outcome | 2017 |
[Ocular graft-versus-host disease: An often misdiagnosed etiology of dry eye syndrome].
Topics: Blepharitis; Cyclosporine; Diagnostic Errors; Dry Eye Syndromes; Graft vs Host Disease; Humans; Male; Middle Aged | 2017 |
Optimizing blepharoplasty outcomes in patients with previous laser vision correction.
Topics: Antirheumatic Agents; Blepharoplasty; Corneal Surgery, Laser; Cyclosporine; Dry Eye Syndromes; Humans; Lubricants; Ophthalmic Solutions; Patient Care Team; Patient Education as Topic; Postoperative Complications; Referral and Consultation; Risk Factors | 2008 |
Evaluation of topical cyclosporine for the treatment of dry eye disease.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Cyclosporine; Drug Evaluation; Dry Eye Syndromes; Female; Fluorescein; Fluorophotometry; Humans; Immunosuppressive Agents; Lissamine Green Dyes; Male; Middle Aged; Ophthalmic Solutions; Prospective Studies; Tears | 2008 |
Ciclosporin use in dry eye disease patients.
Topics: Animals; Cyclosporine; Drug Tolerance; Dry Eye Syndromes; Humans | 2008 |
Occult thyroid eye disease in patients presenting with dry eye symptoms.
Topics: Adult; Aged; Arthritis, Rheumatoid; Cyclosporine; Diagnosis, Differential; Dry Eye Syndromes; Female; Fluorophotometry; Graves Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Oculomotor Muscles; Retrospective Studies; Tears; Treatment Outcome | 2009 |
Neurologic evaluation of acute lacrimomimetic effect of cyclosporine in an experimental rabbit dry eye model.
Topics: Animals; Blinking; Calcitonin Gene-Related Peptide; Cyclosporine; Disease Models, Animal; Dry Eye Syndromes; Immunosuppressive Agents; Lacrimal Apparatus; Male; Ophthalmic Solutions; Parasympathectomy; Rabbits; Tears | 2009 |
Long-term topical cyclosporine treatment improves tear production and reduces keratoconjunctivitis in rabbits with induced autoimmune dacryoadenitis.
Topics: Administration, Topical; Animals; Autoimmune Diseases; Cyclosporine; Dacryocystitis; Drug Administration Schedule; Dry Eye Syndromes; Female; Immunosuppressive Agents; Keratoconjunctivitis; Rabbits; T-Lymphocytes; Tears | 2009 |
The effect of topical cyclosporine A treatment on corneal thickness in patients with trachomatous dry eye.
Topics: Administration, Topical; Aged; Aged, 80 and over; Cornea; Cyclosporine; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Inflammation; Male; Middle Aged; Trachoma | 2009 |
Modalities to decrease stromal herpes simplex keratitis reactivation rates.
Topics: Acyclovir; Administration, Topical; Antiviral Agents; Combined Modality Therapy; Corneal Stroma; Cyclosporine; Drug Therapy, Combination; Dry Eye Syndromes; Electrocoagulation; Eyelids; Glucocorticoids; Herpesvirus 1, Human; Humans; Immunosuppressive Agents; Keratitis, Herpetic; Lacrimal Apparatus; Retrospective Studies; Secondary Prevention; Valacyclovir; Valine; Virus Activation | 2009 |
[0.05% cyclosporine a for treatment of chronic severe ocular surface disease].
Topics: Administration, Topical; Adult; Chronic Disease; Conjunctivitis, Allergic; Cyclosporine; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Intraocular Pressure; Male; Rosacea; Visual Acuity | 2009 |
Restasis for the treatment of 'dry eye' in Aotus nancymaae.
Topics: Animals; Aotidae; Cyclosporine; Dry Eye Syndromes; Immunosuppressive Agents; Male; Monkey Diseases; Treatment Outcome | 2009 |
Efficacy of topical cyclosporine A in the treatment of severe trachomatous dry eye.
Topics: Administration, Topical; Aged; Aged, 80 and over; Cell Count; Cyclosporine; Dry Eye Syndromes; Female; Goblet Cells; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Tears; Trachoma; Treatment Outcome | 2009 |
Efficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eye.
Topics: Chronic Disease; Cyclosporine; Drug Therapy, Combination; Dry Eye Syndromes; Enzyme-Linked Immunosorbent Assay; Female; Fluorophotometry; Glucocorticoids; Humans; Immunosuppressive Agents; Interleukin-6; Interleukin-8; Male; Methylprednisolone; Middle Aged; Ophthalmic Solutions; Tears; Treatment Outcome | 2012 |
Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
Topics: Administration, Topical; Adult; Aged; Conjunctival Diseases; Corneal Diseases; Cyclosporine; Diagnostic Techniques, Ophthalmological; Dry Eye Syndromes; Female; Humans; Hypesthesia; Immunosuppressive Agents; Male; Middle Aged; Prospective Studies; Surveys and Questionnaires; Tears; Young Adult | 2010 |
Ocular manifestations in a community-based cohort of patients with inflammatory bowel disease.
Topics: Acute Disease; Adalimumab; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Cohort Studies; Cyclosporine; Dry Eye Syndromes; Eye Diseases; Female; Humans; Inflammatory Bowel Diseases; Infliximab; Male; Mesalamine; Methotrexate; Middle Aged; Steroids; Treatment Outcome | 2010 |
Minimal clinically important difference for the ocular surface disease index.
Topics: Comorbidity; Cyclosporine; Diagnostic Techniques, Ophthalmological; Disability Evaluation; Dry Eye Syndromes; Emulsions; Female; Humans; Male; Middle Aged; Ophthalmic Solutions; Severity of Illness Index; Surveys and Questionnaires | 2010 |
Drug transport in HEMA conjunctival inserts containing precipitated drug particles.
Topics: Chemical Precipitation; Conjunctiva; Cyclosporine; Diffusion; Drug Administration Routes; Drug Carriers; Drug Delivery Systems; Drug Stability; Dry Eye Syndromes; Methacrylates; Microscopy, Electron, Scanning; Models, Theoretical; Scattering, Radiation | 2010 |
Efficacy of topical cyclosporine A in the treatment of severe trachomatous dry eye: comment.
Topics: Acute Disease; Administration, Topical; Adult; Cyclosporine; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Ophthalmic Solutions; Stevens-Johnson Syndrome; Treatment Outcome | 2010 |
Topical cyclosporine in thyroid orbitopathy-related dry eye: clinical findings, conjunctival epithelial apoptosis, and MMP-9 expression.
Topics: Administration, Topical; Adult; Apoptosis; Conjunctiva; Cyclosporine; Dry Eye Syndromes; Epithelial Cells; Female; Graves Ophthalmopathy; Humans; Immunoenzyme Techniques; Immunosuppressive Agents; In Situ Nick-End Labeling; Male; Matrix Metalloproteinase 9; Middle Aged; Ophthalmic Solutions; Prospective Studies; Treatment Outcome; Young Adult | 2010 |
Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05%.
Topics: Administration, Topical; Adolescent; Adult; Aged; Bone Marrow Transplantation; Child; Child, Preschool; Cyclosporine; Dry Eye Syndromes; Female; Fluorescein; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lissamine Green Dyes; Male; Middle Aged; Neoplasms; Retrospective Studies; Surveys and Questionnaires; Tears; Treatment Outcome | 2010 |
The effect of topical cyclosporine A on clinical findings and cytological grade of the disease in patients with dry eye.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Cell Count; Cyclosporine; Dry Eye Syndromes; Epithelial Cells; Female; Goblet Cells; Humans; Immunosuppressive Agents; Male; Middle Aged; Prospective Studies; Surveys and Questionnaires; Tears; Young Adult | 2010 |
Modalities to decrease stromal herpes simplex keratitis reactivation rates.
Topics: Acyclovir; Administration, Topical; Antiviral Agents; Combined Modality Therapy; Corneal Stroma; Cyclosporine; Drug Therapy, Combination; Dry Eye Syndromes; Electrocoagulation; Eyelids; Glucocorticoids; Herpesvirus 1, Human; Humans; Immunosuppressive Agents; Keratitis, Herpetic; Lacrimal Apparatus; Secondary Prevention; Valacyclovir; Valine; Virus Activation | 2010 |
Ophthalmic delivery of cyclosporine A by punctal plugs.
Topics: Cyclosporine; Delayed-Action Preparations; Dry Eye Syndromes; Eye; Humans; Immunosuppressive Agents; Methacrylates; Models, Biological; Prostheses and Implants; Prosthesis Design | 2011 |
When eyes get dry and what you can try. If artificial tears didn't work, anti-inflammatory cyclosporine drops may.
Topics: Cyclosporine; Dry Eye Syndromes; Humans; Immunosuppressive Agents; Ophthalmic Solutions; Risk Factors | 2010 |
Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease.
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Androstadienes; Chronic Disease; Cohort Studies; Cyclosporine; Dry Eye Syndromes; Eye Pain; Female; Humans; Immunosuppressive Agents; Loteprednol Etabonate; Male; Middle Aged; Retrospective Studies | 2011 |
Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies.
Topics: Animals; Biological Availability; Biological Transport; Cell Culture Techniques; Cell Line; Cell Survival; Cyclosporine; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Dry Eye Syndromes; Eye; Fibroblasts; Immunosuppressive Agents; Kinetics; Male; Mice; Microscopy, Electron, Scanning; Nanoparticles; Particle Size; Rabbits; Solubility; Surface Properties; Tears | 2011 |
Cyclosporine 0.05% ophthalmic emulsion for dry eye in Korea: a prospective, multicenter, open-label, surveillance study.
Topics: Cyclosporine; Dry Eye Syndromes; Emulsions; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Population Surveillance; Prospective Studies; Republic of Korea; Treatment Outcome | 2011 |
In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease.
Topics: Animals; Biological Availability; Chemistry, Pharmaceutical; Cyclosporine; Dry Eye Syndromes; Emulsions; Eye; Female; Kinetics; Ophthalmic Solutions; Prodrugs; Rabbits; Rats; Rats, Inbred Lew; Solubility; Tears; Water | 2012 |
Clinical utility of objective tests for dry eye disease: variability over time and implications for clinical trials and disease management.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Clinical Trials as Topic; Cyclosporine; Diagnostic Techniques, Ophthalmological; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Osmolar Concentration; Prospective Studies; Tears; Time Factors; Treatment Outcome; Young Adult | 2012 |
Efficacy of topical blockade of interleukin-1 in experimental dry eye disease.
Topics: Animals; CD11b Antigen; Cyclosporine; Disease Models, Animal; Dry Eye Syndromes; Female; Fluorescent Antibody Technique, Indirect; Fluorophotometry; Glucocorticoids; Immunosuppressive Agents; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Lymphangiogenesis; Lymphatic Vessels; Methylprednisolone; Mice; Mice, Inbred C57BL; Ophthalmic Solutions; Real-Time Polymerase Chain Reaction; Treatment Outcome | 2012 |
Dry eye medication use and expenditures: data from the medical expenditure panel survey 2001 to 2006.
Topics: Adolescent; Adult; Aged; Cyclosporine; Drug Prescriptions; Drug Utilization; Dry Eye Syndromes; Female; Health Care Costs; Health Care Surveys; Health Expenditures; Health Services Research; Humans; Male; Middle Aged; Pharmaceutical Preparations; Retrospective Studies; United States; Young Adult | 2012 |
Improving awareness, identification, and management of meibomian gland dysfunction.
Topics: Adult; Cyclosporine; Dry Eye Syndromes; Eyelid Diseases; Female; Humans; Keratomileusis, Laser In Situ; Lacrimal Apparatus Diseases; Male; Meibomian Glands; Middle Aged; Ophthalmic Solutions; Tears; Visual Acuity | 2012 |
Emerging treatments for dry eye: some like it hot, while others may prefer a good stimulation.
Topics: Animals; Cyclosporine; Dry Eye Syndromes; Humans; Hyaluronic Acid; Hyperthermia, Induced; Immunosuppressive Agents; Massage; Ophthalmic Solutions; Polyphosphates; Tears; Uracil Nucleotides | 2013 |
Cyclosporine 0.05% ophthalmic emulsion for the treatment of radiation-associated dry eye in children.
Topics: Child; Child, Preschool; Cyclosporine; Dry Eye Syndromes; Emulsions; Eye Neoplasms; Female; Humans; Immunosuppressive Agents; Male; Ophthalmic Solutions; Radiotherapy; Retrospective Studies | 2013 |
Clinical and economic implications of topical cyclosporin A for the treatment of dry eye.
Topics: Administration, Topical; Aged; Cyclosporine; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Patient Satisfaction; United States | 2002 |
[Corneal complications after hematopoietic stem cell transplantation].
Topics: Adolescent; Adult; Aged; Child; Conjunctiva; Corneal Ulcer; Cyclosporine; Diagnosis, Differential; Dry Eye Syndromes; Female; Graft vs Host Reaction; Hematopoietic Stem Cell Transplantation; Humans; Lacrimal Apparatus; Limbus Corneae; Male; Middle Aged; Retrospective Studies; Sjogren's Syndrome | 2003 |
Considerations in the pharmacoeconomics of dry eye.
Topics: Anti-Inflammatory Agents; Cost of Illness; Cyclosporine; Dry Eye Syndromes; Economics, Pharmaceutical; Emulsions; Female; Humans; Male; Managed Care Programs; Middle Aged; Ophthalmic Solutions; Palliative Care; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2003 |
Issues in the use of preservative-free topicals.
Topics: Cyclosporine; Drug Contamination; Dry Eye Syndromes; Humans; Ophthalmic Solutions; Patient Compliance; Pharmacists; Preservatives, Pharmaceutical; Self Administration | 2003 |
Slitlamp biomicroscopy of the tear film of patients using topical Restasis and Refresh Endura.
Topics: Administration, Topical; Cyclosporine; Diagnostic Techniques, Ophthalmological; Drug Therapy, Combination; Dry Eye Syndromes; Emulsions; Glycerol; Humans; Lipid Metabolism; Lipids; Micelles; Microscopy; Ophthalmic Solutions; Patient Compliance; Polysorbates; Tears | 2005 |
[A 0,05% cyclosporine treatment of the advanced dry eye syndrome].
Topics: Administration, Topical; Bone Marrow Transplantation; Cyclosporine; Dry Eye Syndromes; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Sjogren's Syndrome; Time Factors; Treatment Outcome | 2005 |
Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment.
Topics: Administration, Topical; Adult; Chronic Disease; Cyclosporine; Dry Eye Syndromes; Female; Fluorescent Dyes; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Retrospective Studies; Staining and Labeling; Tears; Treatment Outcome | 2007 |
Ophthalmic cyclosporine use in ocular GVHD.
Topics: Administration, Topical; Adolescent; Adult; Aged; Cyclosporine; Dry Eye Syndromes; Female; Fluorescein; Fluorescent Dyes; Fluorophotometry; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Retrospective Studies | 2006 |
[Revision of the recommendations of the Commission on Pharmacotherapy of the German Society for Rheumatology. Recommendations for supportive therapy for Sjögren's syndrome].
Topics: Bromhexine; Cyclosporine; Dry Eye Syndromes; Electric Stimulation Therapy; Expectorants; Humans; Muscarinic Antagonists; Ophthalmic Solutions; Pilocarpine; Quinuclidines; Sjogren's Syndrome; Thiophenes; Xerostomia | 2007 |
Real-world utilization patterns of cyclosporine ophthalmic emulsion 0.05% within managed care.
Topics: Adult; Aged; Aged, 80 and over; Cyclosporine; Drug Prescriptions; Drug Utilization Review; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Male; Managed Care Programs; Middle Aged; Ophthalmic Solutions | 2007 |
Cure for dry eye.
Topics: Administration, Topical; Chronic Disease; Cyclosporine; Dry Eye Syndromes; Humans; Immunosuppressive Agents; Staining and Labeling; Treatment Outcome | 2007 |
Short term effects of topical cyclosporine and viscoelastic on the ocular surfaces in patients with dry eye.
Topics: Adjuvants, Immunologic; Administration, Topical; Cell Count; Chondroitin Sulfates; Conjunctiva; Cyclosporine; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Dry Eye Syndromes; Epithelium; Female; Follow-Up Studies; Goblet Cells; Humans; Hyaluronic Acid; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Tears; Time Factors; Treatment Outcome | 2007 |
Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production.
Topics: Adult; Aged; Cell Count; Chronic Disease; Conjunctiva; Cyclosporine; Dry Eye Syndromes; Emulsions; Female; Fluorescent Antibody Technique, Indirect; Goblet Cells; Humans; Immunosuppressive Agents; Male; Middle Aged; Mucin 5AC; Mucins; Ophthalmic Solutions; Transforming Growth Factor beta2 | 2008 |
Utilization characteristics of topical cycolsporine and punctal plugs in a managed care database.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Combined Modality Therapy; Cyclosporine; Dry Eye Syndromes; Eyelids; Female; Health Care Costs; Humans; Insurance Claim Review; Male; Managed Care Programs; Middle Aged; Prostheses and Implants; Retrospective Studies | 2008 |
Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine.
Topics: Aged; Aged, 80 and over; Cell Count; Cell Division; Conjunctiva; Cyclosporine; Dry Eye Syndromes; Epithelial Cells; Fluorescent Antibody Technique, Indirect; Goblet Cells; Humans; Immunosuppressive Agents; Ki-67 Antigen; Middle Aged; Mitotic Index; Periodic Acid-Schiff Reaction | 2002 |